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ABSTRACT 
 
 
EVOLUTION OF PROSTATIC ACID PHOSPHATASE (ACPP) EXPRESSION IN  
 
HOMINOIDS 
 
 
 
 
 
 
 
By 
 
Kathryn A. Hooper-Boyd 
 
July 2008 
 
 
 
Thesis supervised by Dr. Michael Jensen-Seaman 
 
 Hominoids vary in their mating behavior. Levels of sperm competition vary 
accordingly.  Species in which females mate with a large number of males are expected 
to experience high levels of sperm competition, such as chimpanzee and bonobo, while 
polygynous gorillas likely have little or no sperm competition. Coding regions of several 
seminal proteins have been shown to be experiencing positive selection, but little is 
known about the regulatory regions of these genes. The 1.7 kb upstream promoter region 
of prostatic acid phosphatase (ACPP) of human, bonobo, gorilla, orangutan, gibbon, and 
macaque was cloned into a luciferase reporter vector and transiently transected into a 
human prostate cancer cell line (LNCaP). The in vitro expression levels were measured 
and were found to vary. These results are discussed in terms of mating behavior, sperm  
competition, and the influence of regulatory regions on phenotypic adaptations. 
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Chapter 1 
 
 
Introduction 
 
 
1.1 Primate Mating Systems 
 Much variation exists in the social and mating behavior of the hominoid primates 
(apes and humans) (Figure1). Adult gibbons (Hylobates) live as a monogamous, mated 
pair with dependent offspring (Fleagle, 1999). They are the smallest hominoids and do 
not exhibit sexual size dimorphism. Male investment in infant care is variable among 
gibbon species, however males and females will jointly defend their home territory 
(Fleagle, 1999). Orangutans (Pongo) are solitary animals and have traditionally been less 
studied than other hominoid species.  They exhibit a large degree of sexual size 
dimorphism. They are considered to have a dispersed social system with males having 
overlapping ranges that may allow females to mate with more than one male during a 
reproductive cycle (van Schaik and van Hoof, 1996). Gorillas (Gorilla) live in groups 
consisting of one dominant mature male (silverback) and several adult females with 
dependent offspring (Watts, 1996). They are the largest of the hominoids and exhibit 
extreme sexual size dimorphism (Fleagle, 1999). Males often display aggression towards 
other males, especially unrelated males, and frequently engage in male-male conflict 
(Watts, 1996). The strong degree of physical competition between males sustains a 
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polygynous mating system, in which a dominant male has relatively complete 
reproductive access to mature females in the group (Watts, 1996). Chimpanzees (Pan 
troglodytes) and bonobos (P. paniscus) are the closest extant relatives of humans. There 
is little sexual dimorphism in these species. They live in large social groups consisting of 
a several adult males, several adult females, and dependent offspring (White, 1996).They 
hunt and defend territory cooperatively, with little overt physical competition between 
males (White, 1996). In the large multimale/multifemale groups, females are 
promiscuous and may mate with many males in a single reproductive cycle (Goodall, 
1986). Human (Homo sapiens) social and mating behavior is difficult to classify because 
much variation exists within the species. In most human societies, males will mate with 
one or more females, while females mate with only one male. They are generally 
classified as having monogamous or polygynous mating systems (Fleagle, 1999). 
Macaques are representatives of the Cercopithecoids, or Old World monkeys, and are 
often used as an outgroup for phylogenetic analyses of the hominoids. Macaques are 
similar to chimpanzee and bonobo in their mating systems and live in large 
multimale/multifemale societies. Females will mate with multiple males in a reproductive 
cycle, and levels of sperm competition are high (Fleagle, 1999). It is of note that the 
mating behaviors described above represent generally accepted mating systems, and 
some degree of intra-species variation is likely.  
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Figure 1:  Phylogenetic tree showing the relationship of primate species and their 
mating systems.  Adapted from Fleagle, 1999.  
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1.2 Anatomical Features Correlated with Mating Behavior 
 Mating systems are often associated with specific anatomical traits. Body size 
dimorphism between males and females is typically greatest in polygynous species, such 
as gorilla (Fleagle, 1999). Also, certain features of the testes, sperm, and semen are 
commonly associated with species experiencing a high degree of sperm competition, such 
as in multimale/multifemale groups. For example, relative testes size is larger in 
chimpanzees and bonobos, than in hominoids in which there is little sperm competition 
(Harcourt et al., 1981). Also, the seminal vesicles are larger (Dixson, 1998a) and the 
concentration of motile sperm is higher (Møller, 1988) in species in which the female is 
mating with multiple males during a reproductive cycle. Species with high female 
promiscuity also experience a higher degree of semen coagulation than species with 
monogamous or polygynous mating system (Dixson and Anderson, 2002). Chimpanzees 
and bonobos form a copulatory plug, a mass of coagulated semen that forms inside the 
vagina of the female (Tinklepaugh, 1930). It is likely that this plug is functioning in 
sperm competition to prevent sperm from subsequent males from fertilizing the female 
(Dixson, 1998b), however this has never been demonstrated conclusively. The copulatory 
plug is only found in species with a promiscuous female (Dixson and Anderson, 2002). In 
species where sperm competition is likely not a factor, there is a smaller volume of liquid 
semen, with little or no coagulation occurring in polygynous gorilla (Martin and Gould, 
1977). 
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1.3 Semen Physiology 
A number of proteins have been identified as components of the 
coagulum/copulatory plug. The majority of the protein constituents of semen are 
produced in the seminal vesicles and the prostate. Collectively, these proteins function to 
cause the coagulation or dissolution of the plug. Semenogelins, SEMG1 and SEMG2, are 
the main protein components of coagulated semen (Tauber et al., 1980) Human prostate-
specific transglutaminase, encoded by TGM4, is responsible for cross-linking the 
semenogelins, leading to semen coagulation (Porta et al., 1986). ACPP encodes another 
protein of importance, prostatic-acid phosphatase. Aliases of this gene include ACP and 
PAP .This protein functions as a proteolytic enzyme responsible, along with other 
proteases, for the dissolution of the plug (Brillard-Bourdet et al., 2002)  
 
1.4 Positive Selection on Seminal Proteins 
 Semen from different males overlap inside the female reproductive tract in 
species where females mate with multiple males in a short period of time. In these 
promiscuous species, the seminal fluid proteins are involved in interactions between 
semen from different males. These reproductive proteins are candidates for positive 
selection because of the strong adaptive pressures that are placed on them (Clark and 
Swanson, 2005). A number of seminal protein genes are currently under positive 
selection in chimpanzee (Clark and Swanson, 2005).These genes are involved in either 
the coagulation (TGM4, SEMG1, SEMG2) or dissolution (ACPP, Kallikrein2 (KLK2), 
prostate-specific antigen (PSA)) of semen and the copulatory plug. Other studies found a 
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loss of function of seminal protein genes in species where there is little or no sperm 
competition. Examples include the existence of SEMG1 and SEMG2 as pseudogenes in 
gorilla (Jensen-Seaman and Li, 2003) Also, SEMG1 in certain gibbon species, and TGM4 
in gorilla and some gibbon species (Clark and Swanson, 2005; Carnahan and Jensen-
Seaman, 2008) are non-functional.   
 
1.5 Regulatory Evolution  
 Expression of the genes coding for seminal proteins, as with any protein, is key to 
the relationship between genotype and phenotype (Wray et al., 2003). According to King 
and Wilson (1975), the large phenotypic differences seen between humans and 
chimpanzees is not likely the result of changes in protein coding sequence alone, but it is 
more realistically the result of changes in the expression of these proteins. An example of 
changes in regulatory regions with significant phenotypic consequences is lactase 
persistence in human populations.  A single nucleotide polymorphism (SNP) in a cis-
regulatory element causing an increase in transcription of lactase is the genetic basis for 
lactase persistence (Bersaglieri et al., 2004; Tishkoff et al., 2007). Another example is a 
cis-regulatory SNP that prevents the binding of transcription factor GATA1, responsible 
for expression of Duffy protein (DARC) in erythrocytes, but not other cell types. This 
SNP provides malaria resistance for those individuals who have that genotype 
(Tournamille, et al., 1995).  Identification of gene regulatory elements may contribute to 
the understanding of the mechanism by which variation in expression exists between 
species of primates.  
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1.6 Eukaryotic Transcriptional Regulation 
 Initiation of eukaryotic transcription of protein-coding genes is achieved by RNA 
Polymerase II aided by a number of general transcription factors (Campbell, et al., 2003). 
These general transcription factors function to correctly position RNA Polymerase II at 
the promoter, separate the double-stranded DNA, and release RNA Polymerase II from 
the promoter after initiation of transcription (Alberts et al., 2002). Certain DNA 
sequences are common at the promoter of most protein-coding genes. These DNA 
sequences are recognition sites for many of the general transcription factors and 
complexes that form at the promoter. One important sequence is the TATA box that 
binds a subunit for transcription factor TFIID. TFIID is an important landmark for the 
assembly of the transcription initiation complex (Alberts et al., 2002). While general 
transcription factors are important in initiating transcription in the proximal promoter, 
many elements that also influence regulation of transcription can be found a great 
distance away from the promoter. There are thousands of proteins in the human genome 
that may function as transcriptional regulators.  These regulatory elements may be found 
upstream or downstream of transcription start, and can function as positive or negative 
regulators of transcription (Alberts et al., 2002).  
 
1.7 ACPP Regulation 
 Prostatic acid phosphatase (ACPP) is found in high concentrations in seminal 
fluid. ACPP, among other proteolytic enzymes, is responsible for cleaving the main 
protein constituents of semen, the semenogelins, resulting in a degradation of coagulum 
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shortly after ejaculation (Brillard-Bourdet et al., 2002). The function of prostatic acid 
phosphatase in degradation of semen and the copulatory plug makes it a likely candidate 
for positive selection in species experiencing sperm competition. In fact, the coding 
region of ACPP has been shown to be under positive selection (Clark and Swanson, 
2005). Characterization of the promoter region of ACPP in human has also identified 
elements that may have regulatory potential in this gene. Zelivianski et al. (2002) 
determined that the sequence between -779 and +1 (where transcription start is +1) was 
able to drive low levels of transcription in various cell types, however a dramatic increase 
in prostate-specific expression is driven by the sequence located from -1258 to -779. 
They also determined that the sequence of -1668 to -1356 had a negative effect on 
transcription in a prostate cell line. Others determined that a downstream region from +50 
to +467 may also be functioning in prostate-specific expression in mouse in vivo, but was 
not demonstrated in transiently transfected prostate cancer cells (Shan et al., 2003). Shan 
et al. (1997) identified a number of transcription factor binding sites in the -231 to +50 
region, however none of these appear to be prostate specific.  Potential androgen 
response elements (AREs) have been identified in the upstream promoter region in 
human ACPP (Virkkunen et al., 1994) and GAAATATGATA-like elements, which are  
associated with AREs, have been found to influence transcription of ACPP in the 
presence of androgen (Shan et al., 2003). However, it was also concluded that steroids, 
including androgen, do not regulate expression of human ACPP in -231 to +50 reporter 
constructs transiently transfected in an LNCaP prostate cell line (Shan et al., 1997).  
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Chapter 2 
 
 
Materials and Methods 
 
 
2.1 Creating alignments and building trees   
 To obtain the nucleotide sequence of the 1.7 kb ACPP promoter region of each of 
the hominoids, PCR and sequencing (see below) was performed on the following species: 
chimpanzee (individual PR496, Pan troglodytes), bonobo (individual PR251, Pan 
paniscus), gorilla (individual Josephine, Gorilla gorilla), orangutan (individual PR253, 
Pongo pygmaeus), gibbon (individual PR598, Hylobates syndactyles), and macaque 
(Macaca mulatta, individual NH3).The traces were analyzed and aligned in SeqMan 
(DNAStar, Madison, WI) to create contigs and a consensus sequence of this region. The 
human sequence was obtained from the UCSC genome browser (build hg18; NCBI build 
36.1; Kent et al., 2002). Consensus sequences of the hominoids and human were aligned 
in ClustalW2 (Larkin et al., 2007).  
 
2.2 Characterization of the ACPP promoter  
 The human assembly from March 2006 was used in all analyses.  The 2.2 kb 
ACPP promoter was located in the UCSC genome browser (Kent et al., 2002) on 
chromosome 3, position 133,517,148 to 133,519,347. Configuration of the genome 
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browser plot was established by adding tracks containing various information. To 
establish a general overview of the promoter of ACPP, the following tracks were used: 
Base position, GC percent, RefSeq Genes, CpG Islands, SwitchGear TSS, and 
RepeatMasker.  In order to look at conservation of nucleotide sequence in the promoter 
region, the following tracks were displayed: Base position, RefSeq Genes, 7X Reg 
Potential (regulatory potential calculated from an alignment of human, chimp, macaque, 
mouse, rat, dog, and cow), Conservation (conservation across 28 species of vertebrates), 
Most Conserved (conserved elements predicted by phastCons based on a whole-genome 
alignment of vertebrates and for the subset of placental mammals), 17-Way Conserved 
(conservation in 17 vertebrate species), and 17-Way Most Conserved (conserved 
elements in 17 vertebrate species based on phastCons predictions).  Custom tracks were 
added to the plot, including the area contained in the pGL4.10 [luc2] construct as well as 
previously identified regulatory elements, by formatting the data to the GFF format.  
 
2.3 Transcription factor binding site prediction tools 
 Transcription factor binding sites located in the ACPP promoter were predicted 
using 3 software programs: TFSEARCH (Heinemeyer et al., 1998), MatInspector 
(Genomatix Software GmbH), and Transcription Element Search System (TESS) (Schug 
and Overton, 1998). For each of the programs, the default parameters were used in the 
analysis. For determination of transcription factor binding sites predicted in conserved 
regions of the human ACPP promoter, sequence entered into these programs was 
obtained from the UCSC genome browser March 2006 assembly.  Because prediction 
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programs can generate a large number of false positives, the results were manually 
compared to include only those transcription factor binding sites that were predicted by at 
least 2 of the 3 programs for future consideration. For comparison of predicted 
transcription factor binding sites at variable sites between species, sequence was obtained 
by sequencing the DNA in the lab as explained below and was entered into the 
TFSEARCH program with default parameters. The variable nucleotide plus 10 base pairs 
before and after the nucleotide were put into the prediction program. Differences in 
predicted sites between species were inferred through a manual analysis of the results.  
 
2.4 Primer design  
  Primers were designed to cover the 3 Kilobase promoter region of ACPP and 
ordered from Integrated DNA Technologies (Coralville, IA). This region consists of 2 kb 
of upstream sequence and 1 kb of sequence downstream of the transcription start. To 
design primers for use across hominoid species, the genomic sequence of human and 
macaque were obtained from the UCSC genome browser and aligned using ClustalW2. 
Primers were manually chosen in regions that are conserved between human and 
macaque. The Sequence Manipulation Suite (Stothard, 2000) was used to rule out 
hairpins after the manual choice of primer sequence. Primers were chosen with an ideal 
length of 18-23 nucleotides and an annealing temperature between 55 and 60° C. Forward 
and reverse primers were designed approximately 250 bases apart along the length of the 
sequence in order to cover the 3 kb region in both directions. To design primers for use in 
creating constructs containing 1.7 kb of ACPP upstream promoter (-1593 to +117, where 
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transcription start site is +1), primers were given a 5` tail of approximately 10-15 
nucleotides containing a restriction enzyme site. The forward primer contained a Kpn I 
site while the reverse primer contained a Sac I site. Using separate sites for forward and 
reverse primers ensures that the resulting insert will be ligated in the correct orientation. 
All primers in this study are shown in Table 1.  
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Forward Primers   
    
              Sequence     Name 
TGCAAGTTCCCTTGAATGGT ACPP_F1 
GAGAATGTGATGGCAAAGAG ACPP_F1B 
CTCAGCTCAAAATTTACATGACA ACPP_F2 
GAACTGACAGGTTGGGGAAA ACPP_F3 
GAATCACTGGTCTAAGGTTTC ACPP_F4 
CAGCCACACCAGTCCAGAA ACPP_F5 
CCTTGAATGGTTAATCCTAATC ACPP_F6 
CAGTTCTCCCATATACCACAT ACPP_F7 
GTCCAATTGTCTTAAGGTGTG ACPP_F8 
CAACCTCCACCTCCTGGGTT ACPP_F9 
GCATGGAAATAGGCCCCAAAT ACPP_F10 
TATGTCAACACCTGTATTTCC ACPP_F11 
GATTGTGCCACTGTGCTCCA ACPP_F12 
ACGTGCTACAGGTACCACATTCCAGGGCATCCTATGATC ACPP_pro1710KpnF1
CTCCTCAACATGAGAGCTCCACC ACPP_SacF1 
AGGTGCCAGAACATTTCTCT pGL_4223_F1 
CGCCAGGGTTTTCCCAGTCACGAC M13 F 
Reverse Primers   
    
              Sequence     Name 
CGAGAGAGGAAAGGCAAGAA ACPP_R1 
TTTCAAAAACTCTCATGTAGCCTAT ACPP_R2 
GGTCTCTGGGAAACAATCCA ACPP_R3 
AGGATGCCCTGGAATGTGG ACPP_R4 
TTAGTCACACCTTAAGACAA ACPP_R5 
TAGATAGGGTATGATACAGCGT ACPP_R6  
CTCTGTCAGGTTTGGAAAGG ACPP_R7 
GGAGCCACACTCATAAGTAGT ACPP_R8 
TCCATTTTCCCCAACCTGTC ACPP_R9 
TCTCATGTAGCCTATAGAGGTAT ACPP_R10 
TCTGTAATCCCAGCACTTTGG ACPP_R11 
CTGAGTAGCTGGGATTACAG ACPP_R12 
TGTTGGTTAGGCTGGTCTCCA ACPP_R13 
CACTATGCCTAAGCTTGGTGCAGCTCTGTTGAGGAGAGCTG ACPP_pro338HindR1 
CTGTTTCCTGGAGCTCTGTTGAGGAGAGCTGTTTCTG ACPP_SacR1 
TTACCAACAGTACCGGATTG pGL_92_R1 
GAGCGGATAACAATTTCACACAGG  M13 R 
 
 
Table 1: Primers Sequences for ACPP and pGL4.10 [luc2] 
 
 
13 
2.5 Polymerase chain reaction (PCR)  
  Polymerase Chain Reaction was performed on genomic DNA using the Applied 
Biosystems GeneAmp PCR System 9700 thermocycler. PCR conditions were optimized 
for each primer and species. For PCR on genomic DNA amplified with the purpose of 
sequencing the 3 kb promoter, a standard reaction was used. In a 20µl reaction: 1X 
Eppendorf Taq DNA Polymerase Buffer (1.5mM Mg2+), 250μM dNTPs, 20.0µM forward 
and reverse primers, ~20ng template, 0.5 U Eppendorf Taq, up to 20.0 µl sterile 
molecular biology grade water .  For PCR performed on template destined for constructs, 
a proof-reading Taq was used. In a 50µl reaction: 1X  Takara Taq DNA Polymerase 
Buffer, 400μM dNTPs, 20.0µM forward and reverse primers, ~50ng template, 2.5 units 
Takara LA Taq DNA Polymerase, up to 50µL sterile molecular biology grade water. 
PCR products were column purified using Promega Wizard® SV Gel and PCR Clean-Up 
System to obtain up to 40μg of DNA. PCR products were gel electrophoresed with a 1% 
agarose gel made with 1X SB and visualized under UV light after ethidium bromide 
staining. 4.0µl of PCR product was loaded into a well with 3.0µl of loading buffer. 1.5µl 
of DNA ladder (Fisher exACT Gene Low Range DNA Ladder Plus) was also run along 
with the PCR products to determine product size.  
 
 2.6 TOPO TA Cloning 
 Amplified PCR products of the ACPP promoter of each hominoid species and 
macaque were cloned into a TOPO TA vector (Invitrogen). To ensure that the product is 
correctly ligated into the vector, 3` Adenine-overhangs were added. In a 20µl reaction: 
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10.0µl Taq amplified PCR product, 1X  Taq DNA Polymerase Buffer (1.5mM Mg), 
250μM dNTPs, 0.5 units Taq DNA Polymerase, and up to 20.0µl of sterile molecular 
biology grade water. This reaction was incubated for 15 minutes at 72° C.  The resulting 
product was added to the TOPO cloning reaction. In a 6µl reaction: 0.5-4.0µl PCR 
product, 1.0µl salt solution (1.2M NaCl; 0.06M MgCl2), sterile molecular biology grade 
water up to 5.0µl, and 1.0µl Topo vector. This reaction was mixed and incubated at room 
temperature for 15 minutes (longer time for larger products). The resulting TOPO 
construct was transformed into One Shot® Top 10 chemically competent E.coli by 
adding 2µl of the TOPO cloning reaction into a vial of cells. This was incubated on ice 
for 15 minutes. The cells were then heat -shocked by placing them into a 42° C water 
bath for 30 seconds. They were immediately transferred to ice and 250µl of room 
temperature S.O.C. added. The cells were incubated at 37° C and shaken at 200 rpm for 1 
hour. Last, 20µl, 50µl, 100µl, and 200µl were plated on pre-warmed Luria-Bertani (LB) 
plates with the selective antibiotic ampicillin and incubated overnight at 37° C. The 
TOPO vector contains an ampicillin resistance gene allowing only those colonies 
containing the gene to grow on the selective plates.  
 
 2.7 Screening colonies for the presence of the ACPP insert 
  1 ml of LB medium with ampicillin was placed into a well of a 96 well culture 
plate. Colonies were picked with a sterile toothpick into the 1ml of medium by touching 
the colony, swirling the tip in the 1 ml of medium, and removing the toothpick. 
Typically, 8-16 colonies were picked for each TOPO construct. These 1 ml cultures were 
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placed in the shaking incubator at 37° C and 200 rpm for 6-8 hours. After the incubation 
time, PCR was performed on each 1 ml culture in order to screen for the presence of the 
insert. Primers used for the PCR include M13 forward and reverse primers (Table 1) as 
well as ACPP specific primers designed to work across hominoid species by placing 
them in a region that is conserved between human and macaque. To prepare the 1ml 
culture to use as template, 5.0µl of the culture was added to 50 ml of sterile Molecular 
Biology grade water and heated to 99° C for 15 minutes. In a 20.0µl reaction: 1.0µl 
template (prepared as above), 1X Eppendorf Taq DNA Polymerase Buffer (1.5mM Mg), 
250μM dNTPs, 20.0 mM forward and reverse primers, and 0.5 units Eppendorf Taq 
DNA Polymerase. The resulting PCR products were gel electrophoresed in a 1% Agarose 
gel made with 1X SB and stained with ethidium bromide and visualized under UV light. 
An aliquot of 4.0µl of each product was loaded into a well with 3.0µl of loading buffer 
along with DNA ladder (Fisher exACT Gene Low Range DNA Ladder Plus) to 
determine product size. The presence of a band of the correct size on the gel indicated 
that the colony contained the desired insert. A 50.0µl quantity of the corresponding 
culture was placed in 50 ml of LB broth with ampicillin and placed in the shaking 
incubator at 37°C and 200 rpm for 16-18 hours.  
 
2.8 Midi-Prep plasmid purification 
 Purification of the TOPO plasmid was performed using a QIAGEN HiSpeed® 
Plasmid Midi Kit or a QIAprep Miniprep. For the Midi-prep, the 1 ml starter culture was 
diluted 1/1000 by inoculating 50 ml of LB containing ampicillin with 50μl of the culture. 
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This culture was placed in the shaking incubator at 37º C and 200 rpm for 16-18 hours. 
After the incubation time, the cells were harvested by centrifuging the culture in 50 ml 
centrifuge tubes at 6000 x g for 15 minutes at 4ºC. The QIAGEN protocol for high-copy 
plasmids in a 50 ml culture was followed to purify up to 200μg of high-copy plasmid. 
 
2.9 Mini-Prep plasmid purification 
 To purify the TOPO plasmid using a QIAGEN QIAprep® Miniprep, the 1 ml 
starter culture was diluted 1/100 by inoculating 5 ml of LB containing ampicillin with 
50μl of the culture. This culture was placed in the shaking incubator at 37º C and 200 
rpm for 12-16 hours. After the incubation time, the cells were harvested by centrifuging 
the culture at room temperature in 15 ml conical tubes at 6000 x g for 3 minutes. The 
QIAGEN protocol for QIAprep Spin was followed to purify up to 20 μg of high-copy 
plasmid.  
 
2.10 Sequencing  
 Sequencing was performed on an ABI 3100 Avant Automated DNA Sequencer 
(Applied Biosystems). Both genomic DNA amplified by PCR and plasmid DNA cloned 
in E.coli were sequenced using similar methods. ACPP primers were used for both 
genomic and plasmid DNA, while vector specific primers were also used to sequence 
constructs. These primers include M13 forward and reverse primers for the TOPO 
vectors and pGL4.10 [luc2] primers manually designed to flank the restriction site 
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containing the ACPP insert.  Sequencing of the TOPO and pGL4.10 [luc2] vectors was 
necessary to determine if the insert was correctly ligated into each. In a 20µl reaction:  
2.0 µl BigDye v3.1, 1X BigDye v3.1 Buffer, 1-50 ng  purified plasmid, 3.2 pmol  primer, 
and up to 20 µl of Molecular Biology grade water. The sequencing products were 
purified using Sephadex G-50 as follows: 600.0μl of Sephadex G-50 slurry was added to 
each well in a 96 well filter plate. The plate was centrifuged at 850 x g for 3 minutes and 
the flow through was collected and discarded. The entire sequencing reaction (20.0μl) 
was added to the top of the columns and was centrifuged at 850 x g for 4 minutes, with 
flow through from each well collected in a 96 well plate. After Sephadex purification, the 
samples were dried by placing them in the thermocycler at 90°C for 15 minutes. They 
were resuspended with 10.0µl of Hi-Di Formamide (Applied Biosystems), vortexed, 
denatured at 95°C for 2 minutes, and snap-cooled on ice. SeqMan was used to analyze 
sequence traces and create alignments.  
 
2.11 Making chemically competent E.coli 
 E. coli strain TG1 (a generous gift from Dr. J. McCormick, Duquesne University) 
was streaked from a freezer culture onto an LB plate and incubated 16-18 hours at 37°. A 
colony from this plate was picked with a sterile toothpick by touching the tip of the 
toothpick to the colony and placing it into 3.5 ml of LB. This culture was placed in the 
shaking incubator at 37°C and 200 rpm for 16-18 hours. 300 µl of the 3.5 ml E. coli 
culture was placed in 30 ml of LB broth with no antibiotic (1 in 100 dilution) and placed 
in the shaking incubator at 37°C and 200rpm for 4 hours. 20 ml of the E. coli culture was 
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transferred into a sterile 50 ml centrifuge tube. This was centrifuged at 5000 rpm at 4°C 
for 4 minutes. The supernatant was decanted and the pellet resuspended in 10 ml (1/2 of 
original volume) of 50 mM CaCl2 and placed on ice for 20 minutes. Once again, it was 
centrifuged at 5000 rpm at 4°C for 4 minutes and the supernatant decanted. The pellet 
was resuspended in 2 ml (1/10 of original volume) of 50mM CaCl2. Freezer stocks were 
made of the chemically competent E. coli by adding 1400.0 µl 50%gylcerol/50mM 
CaCL2 solution to 2 ml of the cells and aliquoting 200.0 µl into 1.5 ml screw cap tubes 
for storage at -80ºC.  
 
2.12 Luciferase reporter vectors (pGL4.10 [luc2] and pGL4.70 [hRluc]) 
 The firefly luciferase reporter vector, pGL4.10 [luc2] (Promega), and Renilla 
luciferase vector, pGL4.70 [hRluc] (Promega), were cloned by transforming them into 
chemically competent E.coli. A 200.0 µl freezer stock of E.coli was thawed on ice for 20-
30 minutes. 2.0 µl of the pGL4.10 or pGL4.70 plasmid was added to 200.0 µl of the 
chemically competent E.coli in a 1.5 ml tube. After incubating for 20-30 minutes, this 
was heat shocked by placing in a 42°C water bath for 2 minutes. 1.0 ml of LB broth with 
ampicillin was added to the tube and mixed by inverting 3 times. This was placed 
horizontally in the shaking incubator at 37°C and 200 rpm for 1 hour. 20.0µl, 50.0µl, 
100.0µl, and 200.0 µl were plated on LB plates containing ampicillin along with a 0µl 
control plate and incubated at 37°C for 16-18 hours. The pGL4.10 [luc2] plasmids 
contain an ampicillin resistance gene, enabling only those colonies containing that gene 
to grow on the selective plates. The following day, 2 colonies were separately picked 
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with sterile toothpicks by touching the end of a toothpick to the colony and swirling it in 
3 ml of LB broth with ampicillin. This was placed in the shaking incubator at 37°C at 200 
rpm for 16-18 hours. An aliquot of 50.0 µl of the 3 ml culture was added to 50 ml of LB 
broth containing ampicillin and placed in the shaking incubator at 37°C and 200 rpm for 
16-18 hours. The plasmids were purified using the QIAGEN HiSpeed® Plasmid Midi Kit 
protocol for high-copy plasmids in 50 ml culture as described above.  
 
2.13 Cloning human androgen receptor (hAR) 
 Human androgen receptor (hAR) (cDNA clone; GenBank M34233; ATCC) was 
cloned in E.coli by transforming it in chemically competent cells. To the freeze-dried 
culture, 0.5ml of LB containing ampicillin was added. This was mixed and the entire 
volume added to a 15 ml tube containing 6ml of LB with ampicillin. The tube was placed 
in the shaking incubator at 37ºC and 200 rpm for 20-24 hours. It was then plated at a 
volume of 100.0μl on an LB plate with ampicillin and incubated 16-18 hours at 37ºC. 
After the incubation period, 2 colonies were chosen from the plate with a sterile toothpick 
and placed in 3ml of LB with ampicillin. This was incubated at 37ºC for 8 hours. 50.0μl 
of the 3ml culture was added to 50ml of LB with ampicillin and placed in the shaking 
incubator at 37ºC and 220 rpm for 16-18 hours. A QIAGEN HiSpeed® Plasmid Midi Kit 
was used to purify the receptor following the method described above.  
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2.14 Restriction enzyme digest 
 Purified TOPO plasmids containing the 1.7 kb ACPP promoter insert of each 
species were digested using a double restriction enzyme digest. In a 40.0µl reaction:  23.6 
µl sterile Molecular Biology grade water, 1X Multi-Core Restriction Enzyme Buffer, 4μg 
Acetylated BSA (10µg/µl), 10.0 µg TOPO vector (1.0 µg/µl), 10 units restriction enzyme 
Sac I (10U/µl), and 1.0 unit restriction enzyme Acc 651 (10U/µl). This reaction was 
incubated at 37°C for 2 hours, and then deactivated at 65°C for 15 minutes. The TOPO 
digest was run on a 0.8% Agarose gel made with 1X SB and ethidium bromide at 125 
Volts for 35-40 minutes. After running the gel to separate the 1.7 kb ACPP insert from 
the 4 kb Topo vector, the 1.7 kb insert was manually cut out of the gel. It was purified 
using Promega Wizard®SV Gel and PCR Clean-up System column purification. The 
resulting product was run on a 1% agarose gel stained with ethidium bromide at 150 
Volts for 30 minutes along with Fisher Low Range DNA Ladder to determine the 
quantity of ACPP insert after purification. Purified pGL4.10 [luc2] was also purified 
using a double restriction enzyme digest. In a 20.0 µl reaction: 11.8 µl sterile Molecular 
Biology grade water, 1X Multi-Core Restriction Enzyme Buffer, 2 µg Acetylated BSA, 
5.0 µg pGL4.10 [luc2], 0.5 units restriction enzyme Sac 1 (10U/µl), and 0.5 µnits 
restriction enzyme Acc 651 (10U/µl). This reaction was incubated at 37°C for 2 hours and 
deactivated at 65°C for 15 minutes.  
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2.15 Calf intestinal alkaline phosphatase (CIAP) to remove 5’ phosphates 
 To catalyze the hydrolysis of 5` phosphates from the digested pGL4.10 [luc2], 
calf intestinal alkaline phosphatase (CIAP; Promega) was added directly to the digest 
reaction. The addition of CIAP enhances ligation efficiency by preventing the digested 
vector from ligating back together before the insert is in place. Into the 20 µl digest 
reaction: CIAP 1X Reaction Buffer, 0.05 units CIAP, and sterile Molecular Biology 
grade water up to 50.0 µl. This reaction was incubated at 37°C for 30 minutes, another 
aliquot of 0.05 U CIAP was added to the reaction, and an additional 30 minute incubation 
at 37°C was performed before adding 300.0 µl of CIAP Stop Buffer: 10mM Tris-HCL 
(pH 7.5), 1mM EDTA (pH7.5), 200mM NaCl, 0.5% SDS. The entire reaction was 
purified using Promega Wizard Clean-up System column purification. 4.0 µl of the 
resulting product was run on a 1% Agarose gel made with 1X SB and loaded with 3.0 µl 
loading buffer along with the Fisher Low Range DNA Ladder in order to estimate 
concentration after purification.  
 
2.16 Ligation of insert into luciferase reporter vector 
 The digested and purified ACPP insert of each hominoid species and macaque 
were individually cloned into the digested and purified pGL4.10 [luc2] by joining the 5` 
overhang of one molecule with the 3` overhang of a corresponding strand. This was 
performed through the use of T4 DNA ligase (Promega). For each species, the 
recommended 1:1 molar ratio of vector DNA to insert DNA was assembled as well as 1.0 
µl variations of this ratio in order to optimize the ligation conditions for each individual 
 
22 
reaction. In a 10 µl reaction: 100 ng pGL4.10 [luc2] DNA, 17 ng ACPP insert DNA, 1X 
Ligase Buffer, 1.0 µnit T4 DNA Ligase, up to 10.0 µl Molecular Biology grade water.  A 
reaction containing only pGL4.10 [luc2] and no insert was also set up to control for 
undigested vector backbone. The reactions were ligated at room temperature for 3 hours 
or at 4°C overnight. After the incubation time, the entire 10.0 µl ligation reaction was 
added to 200.0 µl chemically competent E. coli and the plasmids were transformed as 
described above. After transforming the E.coli, the 20.0 µl, 50.0 µl, 100.0 µl, and 200.0 
µl were plated on pre-warmed LB plates with ampicillin.  The plates were incubated at 
37°C for 16-18 hours. Approximately 8-16 colonies from each plate were then picked 
into 1 ml of LB broth with ampicillin in a 96 well culture plate as described above. 
Screening for the presence of the ACPP insert was performed with vector specific and 
gene specific primers as described above. After choosing a culture that appears to contain 
the insert, a 50 ml of LB with ampicillin was inoculated with 50.0 µl of the 1 ml culture 
and placed in the shaking incubator at 37° C for 16-18 hours. The plasmids were purified 
using the QIAGEN Hi-Speed Midi-Prep 50 ml protocol for hi-copy plasmids as described 
above. They were sequenced using vector primers flanking the insert as well as ACPP 
specific primers to ensure the correct ligation of the insert and check for cloning errors.  
 
2.17 Thawing and recovering human cells 
 The prostate cancer cell line, LNCaP, clone FGC (ATCC: CRL-1740), was used 
in all cell culture experiments. 10 ml of complete medium containing 10% Fetal Bovine 
Serum (FBS; Hyclone) and antibiotic was prepared by adding 9 ml of RPMI 1640 
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medium (2mM L-glutamine; ATCC), 1 ml FBS, and 100 µl 100x Penicillin/Streptomycin 
in a sterile 15 ml conical tube (Falcon) and warmed to 37°C in a water bath. The frozen 
LNCaP cells were transferred to a 37°C water bath and continuously agitated until 
thawed.  The vial was wiped with 70% ethanol before placing in a sterile tissue culture 
hood and opening. The cell suspension was then transferred to a 15 ml conical tube 
containing 2 ml of the complete medium with FBS. It was centrifuged for 10 minutes at 
1000 rpm. After removing from the centrifuge, the supernatant was removed and placed 
in a 25 cm2 tissue culture flask (Corning Cell Bind Surface) as a back-up. The cell pellet 
was resuspended in 1 ml of the complete medium with FBS and transferred to a 25 cm2 
tissue culture flask with 4 ml of complete medium. The flasks were placed in a 
humidified 37°C, 5% CO2 incubator for optimal cell growth. The cells were observed 
after 24 hours to ensure attachment of cells to the flask surface. They were observed daily 
to look for changes in growth and an increase in the acidity of the medium indicated by a 
shift in color from red to yellow. The medium was changed every 3-4 days as needed by 
removing and discarding the old medium into a small beaker containing 10% bleach and 
replacing it with pre-warmed, freshly prepared complete medium with FBS.  
 
2.18 Trypsinizing and subculturing human cells 
 When the cells achieved ~80-90% confluency, they were subcultured into 4 new 
flasks. The old medium was removed with a sterile pipette and discarded into 10% 
bleach. The cells were washed in 1 ml of 37°C Hank’s Buffered Salt Solution (HBSS; 
Fisher) to remove residual FBS. This was removed immediately and 1 ml of 37°C trypsin 
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(Sigma) was added to cover the cell layer. The flask was placed in the 37°C incubator for 
3-4 minutes to allow complete detachment of cells from the flask surface. The cells were 
also observed under an inverted microscope to ensure detachment had occurred. 3 ml of 
37°C complete medium was added to the trypsinized cells and they were rinsed 8-10 
times to dislodge remaining cells and cell clumps. 1 ml of this 4 ml cell suspension was 
added to 4 new 25 cm2 tissue culture flasks containing 4 ml of complete medium. The 
flasks were wiped with 70% ethanol and again placed in the 37°C, 5% CO2 incubator.  
 
2.19 Freezing human cells 
 Sterile freezing medium was prepared (20 ml) containing 10% FBS and 10% 
dimethyl sulfoxide (DMSO). In a 50 ml conical tube: 16 ml RPMI 1640 medium (2mM 
L-glutamine), 2 ml FBS, 2 ml DMSO. Once the cells achieved 80-90% confluency, the 
old medium was removed and discarded into 10% bleach. The cells were washed by 
adding 1 ml of 37°C HBSS, which was immediately removed. 1 ml of 37°C trypsin was 
added to the cell layer and the flask was incubated at 37°C for 3-4 minutes to ensure 
detachment of cells. 2 ml of 37°C compete medium was added to the flask and the cell 
suspension was transferred into a sterile 15 ml conical tube. The tube was centrifuged for 
5 minutes at 1500 rpm. The supernatant was removed and the pellet resuspended in 3 ml 
of 4°C freezing medium. 1 ml of the cell suspension was aliquoted into 2 ml cryovials 
and placed in an isopropanol slow freezing apparatus for 1 hour in the -80°C freezer. The 
vials were then transferred to a liquid nitrogen storage freezer for long-term storage.  
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2.20 Counting cells and seeding 12 well plates 
 Cells were washed with 37°C HBSS which was immediately removed and 
discarded. 1 ml of 37°C trypsin was added to the cell monolayer to detach the cells. The 
flask was placed in the 37°C incubator for 3-4 minutes. 3 ml of complete medium was 
added to the flask and cell suspension was pipetted up and down to break up cell clumps. 
In a separate test tube, 500 µl Trypan Blue (Sigma), 300 µl HBSS, and 200 µl of the cell 
suspension were mixed (cell suspension diluted 1:5). Approximately 30 µl of the mixture 
was removed to dispense in the hemocytometer. A small amount of the suspension was 
placed under the coverslip on one side of the hemocytometer and allowed to fill the 
chamber. This was repeated on the other side. The number of viable (bright) cells was 
counted in 5 squares from each side of the hemocytometer. The average number of 
squares was calculated and the viable number of cells calculated with the following 
formula:  
Viable cells/ml = average # cells per square X 5 (dilution factor) X 104 (volume 
correction) 
 To plate 200,000 cells per well in a 12 well plate (Corning CellBind® Surface), the 
following formula was used: 
200,000 cells ÷ # viable cells per ml = # ml of cell suspension to be added to each well 
Complete medium up to 1 ml was added to make the final volume in each well 1 ml.  
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2.21 Transfection optimization with GFP 
 The LNCaP cells were transfected with a plasmid containing Green Fluorescent 
Protein (GFP) (GFP-pFLAG cmv 5a/DH5α) to optimize transfection efficiency using 
FuGENE HD transfection reagent (Roche). This construct was a generous gift from Dr. 
P. Auron, Duquesne University. A 12-well plate (Corning CellBind®) was seeded with 
200,000 cells per well. RPMI1640 medium (no FBS or antibiotic) was used as a diluent 
to prepare DNA with a concentration of 2 µg per 100 µl. 100 µl of the mixture was 
placed in 6 separate tubes. To these tubes, 0µl, 3µl, 4µl, 5µl, 6µl, and 8µl of FuGENE 
transfection reagent was added to the tubes for a 0:2, 3:2, 4:2, 5:2, 6:2, and 8:2 ratio of 
FuGENE to DNA, respectively. After a 15 minute incubation, 48 µl was added to ½ of 
the wells by pipetting in a drop-wise manner to ensure even application to the cells. After 
30 minutes, 48 µl was added to the remaining 6 wells of cells. The plates were placed in 
the 37ºC, 5%CO2 incubator for 48 hours before viewing the cells with an inverted 
confocal microscope.  
 
2.22 Transfection pGL4.10 constructs 
 It was determined through optimization with the GFP plasmid that a 3:2 ratio of 
FuGENE to DNA and a 30 minute incubation time was most effective in transfection of 
the LNCaP cells. 12-well plates (Corning CellBind®) were seeded with 200,000 cells per 
well. The concentration of the pGL4.10 [luc2] constructs containing the ACPP promoter 
of each hominoid species was determined by UV spectroscopy. Separate cocktails for 
each species and an empty vector were set up to contain1.0µg of pGL4.10 construct (or 
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empty vector for a control), 0.1 µg of pGL4.70 (Renilla), 1.5 µl FuGENE transfection 
reagent, and up to 1 ml of complete medium per well. For experiments with androgen 
receptor cotransfection, 0.2 µg/well of androgen receptor was also added to the cocktail 
before bringing final volume to 1.0 ml per well. The cocktails were incubated at room 
temperature for 30 minutes before 50.0 µl of the cocktail was added in a drop-wise 
manner to each appropriate well on the 12-well plate. The plates were then placed back in 
the 37ºC, 5% CO2 incubator.  
 
2.23 Addition of R1881 
 Methytrienolone (R1881) (PerkinElmer Life Sciences, Inc), a synthetic androgen, 
was added to select 12-well plates in order to test the effect of androgen on gene 
expression. To make 10 mM stocks, 5 mg of R1881 was diluted in 1.76 ml 100% ethanol. 
100μM working stocks of R1881 were made by adding 10μl of the 10 mM stock to 
1000μl of ethanol. To apply a 10 nM treatment to selected wells of the 12-well plate, the 
old medium was removed from each well and discarded into 10% bleach. 1 μl of 100 μM 
R1881 was added to 10ml of complete medium and 1 ml of this added to select wells. For 
a vehicle control, 1 μl of 100% ethanol was added to 10 ml of complete medium and 1 ml 
of this was added to other remaining wells. The addition of androgen was performed 24 
hours after transfection.  
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2.24 Dual-luciferase reporter assay 
 The cells of the 12-well plate were passively lysed by first removing the old 
medium and washing the monolayer with 250 μl of 1X Phosphate Buffered Saline 
(PBS;Fisher). The PBS wash was removed and 250 μl of 1X Passive Lysis Buffer (PLB) 
(Promega) was added to each well. The plates were gently rocked for 15 minutes to 
ensure complete lysis of the cells. From each well of the 12-well plate, 20 μl of the 
resulting lysate was transferred to a well in a 96 well plate where the reporter assay was 
performed. 20 μl of PLB was also placed in one well of the plate to control for 
background luminescence. Luciferase Assay Reagent II (LAR II) and Stop & Glo® 
Reagent were prepared using the protocol and reagents provided in the Dual-Luciferase® 
Reporter Assay System kit (Promega). Excess reagent was aliquoted into 1.5 ml screw 
cap tubes (for LAR II) and 1.5 ml siliconized polypropylene tubes (for Stop & Glo®) for 
storage. The reagents were brought to room temperature before use in the assay. The 96 
well plate and the reagents were placed into the auto-injecting Veritas microplate 
luminometer version 1.1 (Turner Biosystems). The luminometer first dispenses 100 μl of 
LAR II to measure the firefly luciferase activity, then dispenses 100 μl of the Stop & Glo 
reagent to quench the firefly luciferase activity and measure Renilla luciferase activity. 
After the luminescence was recorded, the ratio of relative luminescence of firefly 
luciferase to Renilla luciferase was calculated. This was done by subtracting the firefly 
luminescence recorded from the PLB from the firefly luminescence recorded in the 
sample in question and dividing this number by the Renilla luminescence recorded in the 
plain PLB subtracted from the Renilla luminescence recorded in the same sample well. 
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This relative ratio was compared across treatments and hominoid species to determine 
levels of expression. For all experiments, one assay per transfection was performed.     
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Chapter 3 
 
 
Results 
 
 
3.1 Characterization of ACPP promoter 
 The 2.2 kb region upstream of ACPP was viewed through the UCSC genome 
browser using the March 2006 Human Assembly.  This region is located on chromosome 
3 in position 133,517,148 to 133,519,347. General characterization of the putative 
promoter was made by means of various tracks available to customize the view (Figure 
2). A number of points were noted from this first examination. The first exon of the gene 
contains coding sequence. The RefSeq Genes and Switchgear TSS tracks illustrate that 
there is not evidence of an additional exon upstream of the first annotated exon. The 
presence of elements related to transcription, such as TATA at -27, CAAT at -40, and 
ATG at +51 (Shan et al. 1997), are further indicative that the predicted first exon is a 
coding exon.  There are no CpG islands predicted in the region. This is of note because 
promoter regions are often GC rich as to be involved with transcriptional regulation 
through methylation. Finally, there are several short interspersed nuclear elements 
(SINEs) in the promoter taking up over 51% of the 2 kb directly upstream from the 
transcription start site. This is higher than the genome average and much higher than 
most promoter regions (Venter et al., 2001).  
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Figure 2: Overview of ACPP promoter region in UCSC genome browser. A 2.2 kb 
region of the ACPP promoter, located on chromosome 3 at position 133,517,148 to 
133,519,347, as viewed in the UCSC genome browser (Kent et al., 2002). The 1.7 kb 
area included in the pGL4.10 [luc2] constructs is displayed (“ACPP construct”).  
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3.2 Conservation across species 
 To predict functionally important regions of the promoter that may play a role in 
the regulation of ACPP gene expression, the UCSC genome browser was used to explore 
areas of conservation across a number of species (Figure 3). The same chromosome 
region and position were used as in previous analyses. A number of peaks of 
conservation were discovered in the 1.5 kb region upstream of transcription and in the 
area immediately downstream of the first exon. For 5 of the highest peaks, 4 upstream 
and 1 downstream of transcription start, the human sequence was obtained from the 
browser and put through a suite of transcription factor binding site prediction programs 
(TFSEARCH, MatInspector, TESS). The results of the transcription factor binding site 
predictions varied between the programs, likely with a large number of false positive 
results. In order to increase the likelihood of identifying true positive results, the 
transcription factors that were predicted in at least 2 of the 3 programs are shown in Table 
2.  
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Figure 3: Peaks of high conservation are located in the ACPP promoter. Within the 
ACPP region inserted into the pGL4.10 [luc2] construct, there are a number of peaks of 
high conservation. Conserved elements 1-5 were used in transcription factor binding site 
prediction.  
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Conserved 
element Position Predicted TFBS 
1 chr3: 133518235-133518308 cap, HSF, Bcd, ADR1, GCN4, Ik-2, CRE-Bp 
2 chr3: 133518721-133518804 MZF1, RoRalp, CdxA. Nkx-2 
3 chr3: 133518101-133518117 c-Myb 
4 chr3: 133518884-133518926 Nkx-2, S8, ADR1, Dfd 
5 chr3: 133519226-133519263 HSF, cap, C/EBPb, Oct-1, Dfd, SRY, Nkx-2, HSF2 
 
 
 
 
Table 2: Transcription factor binding sites predicted in conserved elements in the 
ACPP promoter.  Input of the sequence of 5 conserved elements into 3 separate 
transcription factor binding site prediction programs produced a large number of results. 
Transcription factor binding sites that were predicted in at least 2 of the 3 programs are 
summarized in the table.   
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3.3 Location of previously identified TFBS 
 In order to visualize previously predicted transcription factor binding sites and 
experimentally established regulatory regions of the ACPP promoter, the UCSC genome 
browser was again used to plot the location of these elements (Figure 4). Included in the 
plot are putative Androgen Response Elements (AREs) (Shan et al., 2003), DNAse 
footprinting areas (Shan et al., 1997), and areas demonstrated to be important for 
upregulation or downregulation of expression (Zelivianski et al., 2002).  These elements 
are mainly located upstream of transcription start, however two AREs are located 
immediately following the first exon and one DNAse footprinting area is located past 
transcription start in the 5’ untranslated region.  
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Figure 4: Elements important to transcriptional regulation of ACPP in human have 
been previously reported. Others have indentified elements that may be involved in the 
transcriptional regulation of ACPP in humans. These elements include regions of 
upregulation and downregulation in vitro (Zelivianski et al., 2002), DNA footprinting 
regions (Shan et al.,1997), and androgen response elements (ARE) (Shan et al., 2003). 
The location of these elements relative to the area covered by the ACPP construct are 
plotted.    
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3.4 Optimization of transfection methods with GFP vector 
 Optimization of transfection methods in the prostate cancer cell line, LNCaP, was 
performed by transfecting a vector containing green fluorescent protein (GFP) into the 
cell line using varying ratios of µl of FuGENE transfection reagent to µg of vector DNA. 
These ratios were 0:2, 3:2, 4:2, 5:2, 6:2, and 8:2. The incubation time for the transfection 
complex was also optimized, adding the complex to the ½ of the cells after a 15 minute 
incubation, and adding the complex after a 30 minute incubation for the remaining ½ of 
the cells. After 48 hours and 72 hours, the same 12-well plate was viewed using an 
inverted fluorescent microscope and multiple comparisons were made of cell number and 
fluorescence among the many treatments. The different ratios of transfection reagent to 
DNA were compared to each other at the 48 hour observation, the 72 hour observation, 
and between the 48 and 72 hour observations. Similarly, the incubation times of the 
transfection complex were compared between the 15 minute and 30 minute incubation 
times at the 48 hour observation, the 72 hour observation, and between the 48 hour and 
72 hour observation. While no formal statistical analyses were made, qualitative and 
quantitative observations as well as manual counting of cells provided some general 
results (Figure 5). The transfection was successful under all experimental conditions; 
however the lowest non-zero ratios of FuGENE transfection complex to vector DNA 
produced the greatest fluorescence after both 48 and 72 hours post-transfection. It was 
also established that 72 hours post-transfection produced the greatest fluorescence 
overall, with approximately 25% transfection efficiency. It was therefore determined that 
future transfection experiments using the LNCaP cell line would be performed with a 3:2 
FuGENE to DNA ratio and observed 72 hours after transfection.  
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                              a                     b 
 
Figure 5: Optimization of Transfection Methods in the LNCaP Cell Line with a 
GFP Containing Vector.  The transfection optimization experiment was designed to 
compare ratios of transfection reagent to DNA, as well as examine incubation time of the 
transfection complex before adding it to the cells. The time after transfection required for 
optimal fluorescence was also noted. It was concluded that the lower levels of 
transfection reagent to DNA, a 30 minute transfection complex incubation time, and a 72 
hour post transfection period before observing fluorescence were the optimal conditions 
in the LNCaP cell line. Shown is the same well of cells viewed with normal light (a) and 
with a fluorescent light source (b) under optimal conditions: 3:2 ratio of FuGENE to 
DNA, 30 minute incubation, 72 hours post-transfection.  
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3.5 Human ACPP promoter drives expression in LNCaP cells 
 To determine if the pGL4.10 [luc2] construct containing the human ACPP 
promoter (-1593 to +117) was able to drive transcription in vitro in the LNCaP cell line, 
the relative luminescence produced by the human construct was compared to the relative 
luminescence produced by the empty vector. The human construct and empty vector were 
transfected in duplicate into cells in alternating wells of the same 12-well tissue culture 
plate using the lipid-based transfection reagent, FuGene. pGL4.10 [hRluc] was also 
transfected to control for transfection efficiency. The LNCaP prostate cancer cell line is 
known to be stimulated by androgen and therefore synthetic androgen, methytrienolone 
(R1881), was applied (10nM) to select cells in the plate. An ethanol control was used to 
determine if the vehicle was affecting transcription levels. Charcoal-stripped FBS 
(HyClone) was used to make the complete medium that was applied during the androgen 
treatments to ensure that excess androgen was not introduced through use of FBS. In all 
treatments, the human promoter was able to drive transcription ~5-fold more effectively 
than the empty vector under the same conditions (Figure 6). This difference was 
significant in the 10 nM R1881 treatment (p=0.0076). In the no treatment transfections 
(p=0.1709) and vehicle control transfections (p=0.2147), the difference was not 
significant between the human and empty constructs. 
 
 
 
  
 
40 
Expression by the Human ACPP Promoter
 in LNCaP Cells
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Figure 6: The human ACPP promoter drives transcription in the in vitro system. The 
pGL4.10 [luc2] construct containing the human ACPP promoter was able to drive 
transcription to a higher level than the empty vector in the LNCaP cell line. The 
transfection of the human construct and empty vector was carried out under three 
experimental conditions. Relative luminescence was used to assess expression driven by 
the promoter. In all cases, the expression driven by the human promoter was higher than 
the empty vector, and this was significant in the 10 nM R1881 treatment.  T-test: no 
treatment (p=0.1709), 10nM R1881 (p=0.0076), EtOH (p=0.2147) n=2.  
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3.6 Hominoid species vary in transcription 
 The difference in expression between the ACPP promoters of the hominoids and 
macaque was analyzed by comparing the relative luminescence of each in an in vitro 
system (Figure 7). The pGL4.10 [luc2] constructs containing 1.7 kb of the upstream 
promoter of human, bonobo, gorilla, orangutan, gibbon, or macaque were transfected into 
the LNCaP cells. The pGL4.70 [hRluc] vector producing Renilla luciferase was also 
cotransfected to control for transfection efficiency. These transfections were performed in 
quadruplicate (n=4). 72 hours post-transfection, the dual luciferase reporter assay was 
completed and the relative luminescence measured in a luminometer. The means of the 
samples were significantly different (ANOVA; p<0.0001), and multiple pairwise 
comparisons using Tukey’s post test were also significant (Table 3). These include a 
significant difference in expression between bonobo and human (p<0.001), gorilla 
(p<0.001), orangutan (p<0.001), and gibbon (p<0.001). There was a significant 
difference between gorilla and human (p<0.001), orangutan (p<0.01), gibbon (p<0.05), 
and macaque (p<0.001).  The difference between human and gibbon (p<0.05) and 
macaque (p<0.001) was also significant.  
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Figure 7: Differential expression by the ACPP promoter exists between the 
hominoids. Levels of relative luminescence driven by the ACPP promoter of human, 
bonobo, gorilla, orangutan, gibbon, and macaque were compared under normal 
conditions with no application of R1881 or cotransfection of hAR receptor. There is a 
significant difference in expression between the species (ANOVA; p<0.0001; n=4)  
 
 
 
 
Table 3: Tukey’s Multiple Comparison Post-Tests (No Treatment) 
 Human Bonobo Gorilla Orangutan Gibbon Macaque
Human             
Bonobo p<0.001           
Gorilla p<0.001 p<0.001         
Orangutan p>0.05 p<0.001 p<0.01       
Gibbon p<0.05 p<0.001 p<0.05 p>0.05     
Macaque p<0.001 p>0.05 p<0.001 p<0.001 p<0.001   
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3.7 Hominoid species vary in transcription with androgen 
 R1881 was applied to the LNCaP cells after transfection to determine if the 
expression of ACPP is in part affected by androgen (Figure 8). The pGL4.10 [luc 2] 
constructs containing the ACPP promoter of the hominoids and macaque were 
transfected in the LNCaP cells in quadruplicate (n=4), along with the pGL4.10 [hRluc] 
vector.  24 hours after transfection, 10 nM R1881 was applied to the cells in new medium 
containing charcoal-stripped FBS. The luciferase reporter assay was performed 72 hours 
after transfection and the levels of relative luminescence were measures in a 
luminometer.  Means of species were significantly different (ANOVA; p<0.001) as were 
many of the pairwise comparisons (Tukey’s post-test). These include a significant 
difference in expression between human and orangutan (p<0.05), gibbon (p<0.01), and 
macaque (p<0.05). There were also significant differences in expression between and 
bonobo and other species: gorilla (p<0.001), orangutan (p<0.01), gibbon (p<0.001), and 
macaque (p<0.01). Finally, gorilla was significantly different than orangutan (p<0.001), 
gibbon (p<0.01) and macaque (p<0.001) (Table 4).  
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Figure 8: Differential expression by the ACPP promoter exists between the 
hominoids when treated with 10nM R1881.  Levels of relative luminescence driven by 
the ACPP promoter of human, bonobo, gorilla, orangutan, gibbon, and macaque were 
compared after application of 10 nM R1881. There is a significant difference in 
expression between the species (ANOVA; p<0.001; n=4).  
 
 
 
Table 4: Tukey’s Multiple Comparison Post-Tests (10 nM R1881) 
 Human Bonobo Gorilla Orangutan Gibbon Macaque
Human             
Bonobo p>0.05           
Gorilla p<0.001 p<0.001         
Orangutan p<0.05 p<0.01 p<0.001       
Gibbon p<0.01 p<0.001 p<0.01 p>0.05     
Macaque p<0.05 p<0.01 p<0.001 p>0.05 p>0.05   
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3.8 Human ACPP promoter drives expression with androgen receptor and 
androgen 
 The effect on expression of cotransfecting the hAR into the LNCaP cells was 
examined after differences in expression were found to exist among hominoids with the 
application of R1881. This was first tested in human by cotransfecting 0.2μg hAR with 
the transfection of the pGL4.10 [luc2] construct and pGL4.70 [hRluc] control vector to 
ensure that expression was greater than the empty vector. Also, 1nM or 10nM R1881 was 
applied 24 hours after transfection for certain experimental conditions. Both experimental 
conditions were performed in triplicate. After comparing expression levels to the empty 
pGL4.10 [luc2] vector, it was determined that the pGL4.10 [luc2] construct containing 
1.7 kb of the human ACPP promoter was able to drive transcription to significantly 
higher levels than the empty vector under 1nM R1881 (p=0.0094) and 10nM 
R1881(p=0.0238) experimental conditions (Figure 9). There was not a significant 
difference between the human ACPP construct under 1 nM versus 10 nM R1881 
(p=0.3422). 
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Figure 9: The human promoter drives transcription in the presence of androgen 
after cotransfection with androgen receptor. The pGL4.10 [luc2] construct containing 
the human ACPP promoter was able to drive transcription to a higher level than the 
empty vector in the LNCaP cell line after cotransfection with hAR and addition of 
R1881. The transfection of the human construct and empty vector was carried out under 
two experimental conditions. Relative luminescence was used to assess expression driven 
by the promoter. In both cases, the expression driven by the human promoter was higher 
than the empty vector, and this was significant in the 1 nM R1881(p=0.0093) and 10 nM 
R1881 (p=0.0238) treatments (n=3). 
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3.9 Hominoid species vary in transcription with androgen receptor and 
androgen 
 To further examine the effect of androgen on ACPP expression in hominoids and 
macaque, hAR was cotransfected into the LNCaP cells at the same time the pGL4.10 
[luc2] constructs containing the hominoid promoter and pGL4.20 [hRluc] vector were 
transfected.  hAR is the receptor that functions to bind the androgen molecule. A final 
concentration of10nM R1881 was also applied to the cells in charcoal-stripped medium 
24 hours after transfection. The relative luminescence of all species was compared 72 
hours after transfection. The means of the samples were significantly different (ANOVA; 
p<0.001) and multiple pairwise comparisons that were also significant (Tukey’s post-test) 
(Figure 10). These include significant differences between human and bonobo (p<0.05), 
gorilla (p<0.001), and gibbon (p<0.05). There is also a significant difference between 
bonobo and gorilla (p<0.001), orangutan (p<0.01), gibbon (p<0.001), and macaque 
(p<0.001). Finally, a pairwise comparison finds gorilla expression significantly different 
than orangutan (p<0.001) and macaque (p<0.01) (Table 5).  
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Figure 10: Differential expression by the ACPP promoter exists between the 
hominoids after cotransfection with 0.2µg hAR and addition of 10nM R1881. Levels 
of relative luminescence driven by the ACPP promoter of human, bonobo, gorilla, 
orangutan, gibbon, and macaque were compared after cotransfecting with 0.2μg hAR and 
application of 10 nM application of R1881. There is a significant difference in expression 
between the species (ANOVA; p<0.001; n=4).  
 
 
Table 5: Tukey’s Multiple Comparison Post-Tests (0.2 μg hAR + 10 nM R1881) 
 Human Bonobo Gorilla Orangutan Gibbon Macaque 
Human             
Bonobo p<0.05           
Gorilla p<0.001 p<0.001         
Orangutan p>0.05 p<0.01 p<0.001       
Gibbon p<0.05 p<0.001 p>0.05 p>0.05     
Macaque p>0.05 p<0.001 p<0.01 p>0.05 p>0.05   
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3.10 Androgen receptor increases expression in some species 
 To determine if hAR is responsible for changes in expression within species after 
application of 10nM R1881, the relative luminescence of the 10nM treatment was 
compared to the relative luminescence of the 0.2µg hAR + 10nM R1881 treatment. A t-
test was performed on the samples from each treatment (n=4) and it was determined that 
the expression driven by the ACPP promoter was significantly higher with the 0.2µg 
hAR+ 10nM R1881 treatment than with the 10nM R1881 alone in certain species (Figure 
11). These species include bonobo (p=0.007), gorilla (p=0.007), and orangutan 
(p=0.0291). The other species did not exhibit the same trend of increased expression with 
cotransfection of hAR and expression was not significantly different between the 
treatments: human (p=0.9672), gibbon (p=0.0811), and macaque (p=0.2694).  
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Effect of hAR on Expression with Addition of 10nM R1881
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Figure 11: Bonobo, gorilla, and orangutan show significantly increased expression 
by the ACPP promoter with the addition of 0.2µg of hAR and 10nM R1881 than 
with 10nM R1881 alone.  The within species relative luminescence of human, bonobo, 
gorilla, orangutan, gibbon, and macaque were compared between the 10nM R1881 and 
0.2µg + 10nM R1881 experimental treatments. Bonobo (t-test; p=0.0070), gorilla (t-test; 
p=0.0070), and orangutan (t-test; p=0.0291) showed significantly increased expression by 
the ACPP promoter when 0.2µg hAR was cotransfected and cells were treated with 
10nM R1881 than with the treatment with 10nM R1881 alone.  
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3.11 Human ACPP relative luminescence is variable  
 Because much week-to-week variation in relative luminescence ratios of the 
human ACPP construct was apparent after examination of multiple treatments, 
comparisons of the ratios were made based on treatment type and day of transfection 
(Figure 12). After graphing these values, it was determined that the relative luminescence 
ratios from all experimental conditions performed in the first week were higher (1.5 to 5 
times higher) and had larger standard errors than the following human transfection. The 
levels of relative luminescence and measures of error for the second and third 
transfections of the human construct were more consistent with levels of luminescence 
and error seen in transfections of the other hominoid constructs.  
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Figure 12: Relative luminescence ratios by the human ACPP promoter were 
variable.  Luminescence ratios differ by day of transfection. Transfections performed on 
the same day are indicated by the same graph pattern. The first transfections performed 
(white) are much higher with larger errors than transfections performed second (stripe) or 
third (black).  
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3.12 Nucleotide variation exists between species 
 After finding significant differences in expression of ACPP in bonobo and gorilla, 
the variation in nucleotide sequence between these species and human were compared to 
identify changes that may be leading to differential expression. The sequence of the 1.7 
kb region of ACPP promoter contained in the pGL4.10 [luc2] constructs of human and 
bonobo were aligned in Mega (Tamura et al., 2007) and variable sites were identified. 
These sequences were then put into TFSEARCH to determine predicted transcription 
factor binding sites for the region. In 22 nucleotide differences between human and 
bonobo, there were 14 changes that occurred in only the chimpanzee and bonobo lineage, 
with 9 of those changes exclusive to bonobo. The other differences between human and 
bonobo were shared by all of the apes. The nucleotide changes in the chimpanzee and 
bonobo lineage led to a gain of 11 predicted transcription factor binding sites that differed 
from human, with 9 of those being specific to bonobo (Table 6). The same comparison 
was made between the 1.7 kb region of human and gorilla. In the comparison between 
human and gorilla, 31 variable nucleotides were found. Of these, 17 were exclusive to 
gorilla while the additional changes were shared with other apes. The 17 gorilla-specific 
nucleotide changes resulted in a loss of 12 putative transcription factor binding sites that 
are predicted in human (Table 7).   
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 Table 6: Human and Bonobo: Differences in Predicted Transcription Factor 
Binding Sites  
Species Sequence Exclusive TFBS Occurrence Position 
          
Human TCTGCCATTATGATAGAAATA NIT2,Skn-1,Nkx-2    193 
Bonobo TCTGCCATTAGGATAGAAATA GATA-2 all apes   
          
Human AGTTCCATCAGTCTGGATCGC     244 
Bonobo AGTTCCATCAATCTGGATCGC 
CDP CR, CdxA, 
GATA-1 Bonobo only   
          
Human TTTTTGTTGTTGTTTGTTTGT HNF-3b, HFH-2   500 
Bonobo TTTTTGTTGTCGTTTGTTTGT   Chimp & Bonobo   
          
Human  GGCATGTGCCACCACGCCAGG     654 
Bonobo GGCATGTGCCCCCACGCCAGG ADR1 Bonobo only   
          
Human TGTATTTTTAGTAGAGATGGG     690 
Bonobo TGTATTTTTATTAGAGATGGG Brn-2, Hb Chimp & Bonobo    
          
Human GATCTGCCCACCTCGGCCTCC     757,761 
Bonobo GATCTGCCCATCTCAGCCTCC GATA-1, GATA-2, cap Bonobo only   
          
Human GCTGGGATTACAGACATGAGC     784 
Bonobo GCTGGGATTATAGACATGAGC MATalp Bonobo only   
          
Human TTCAGTCCTATAACTTTGGAC CdxA   966 
Bonobo TTCAGTCCTACAACTTTGGAC   all apes   
          
Human TAAAGAAAAGATAAAAGTAAA No difference   1081 
Bonobo TAAAGAAAAGCTAAAAGTAAA   Chimp & Bonobo   
          
Human CAAGGCAGGCGGATCATGCGG No difference   1157 
Bonobo CAAGGCAGGCAGATCATGCGG   Chimp & Bonobo   
          
Human TGCAGTGAGCTGAGATTGTGC Ap-4   1329 
Bonobo TGCAGTGAGCCGAGATTGTGC GATA-2 all apes   
          
Human GTGCCACTGTGCTCCAGCCTG No difference   1345 
Bonobo GTGCCACTGTCCTCCAGCCTG   all apes   
          
Human TCCAGCCTGGATGACAGAGCA Skn-1   1358 
Bonobo TCCAGCCTGGGTGACAGAGCA AP-1 all apes   
          
Human ATGACAGAGCAAGACTCTGTCT No difference   1367 
Bonobo ATGACAGAGAGAGACTCTGTCT   Bonobo only   
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(Table 6: Continued) 
Species Sequence Exclusive TFBS Occurrence Position 
          
Human GCAAGACTCTGTCTCAAAAAAA     1376 
Bonobo GCAAGACTCTCACTCAAAAAAA cap Bonobo only   
          
Human AAAAAAAAAACAAAAAACAAA BR-C Z   1394 
Bonobo AAAAAAAAAAAAAAAAACAAA   all apes   
          
Human TGAAAACAAGGATAGAAATGT No difference   1416 
Bonobo TGAAAACAAGAATAGAAATGT   all apes   
          
Human CAGCTTTCCCCGCTCTTGGCC MZF1, ADR1   1478 
Bonobo CAGCTTTCCCTGCTCTTGGCC   Chimp & Bonobo   
          
Human AACTTTACTACTTATGAGTGT     1595 
Bonobo AACTTTACTATTTATGAGTGT BR-C Z all apes   
 
 
 
 
 
Table 6: The sequences of human and bonobo were aligned and variable nucleotides 
between the species were noted. The variable nucleotide plus 10 nucleotides before and 
after were put into the TFSEARCH transcription factor binding site prediction program. 
The predicted transcription factors that are exclusive to one species are noted on the same 
line as that species’ nucleotide sequence. The occurrence of that change in one or more 
species is also noted. There were 22 nucleotide changes between human and bonobo, 9 of 
which were specific to bonobo, resulting in a gain of 9 more transcription factor binding 
sites than what was predicted in human. 
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Table 7: Human and Gorilla: Differences in Predicted Transcription Factor Binding 
Sites 
Species Sequence TFBS-TFSearch Occurrence Position 
          
Human GCAATGTACCAGGAAACAGGTTG HSF   69 
Gorilla GCAATGTACCATGAAACAGGTTG   Gorilla only   
          
Human GTAAACCATTGTTCTCCCTCT Sox-5   95 
Gorilla GTAAACCATTTTTCTCCCTCT dl, CdxA Gorilla only   
          
Human TCTGCCATTATGATAGAAATA NIT2, Skn-1, Nkx-2   113 
Gorilla TCTGCCATTAGGATAGAAATA GATA-2 all apes   
          
Human TCTGCCCCCAAATCTTGCAAA     149 
Gorilla TCTGCCCCCACATCTTGCAAA GATA-1 Gorilla only   
          
Human TCTGGATCGCCTTTTGTAGTG TATA   255 
Gorilla TCTGGATCGCTTTTTGTAGTG   Gorilla only   
          
Human AGTGTCCCCAGTGAGATCATA     272 
Gorilla AGTGTCCCCAATGAGATCATA NF-Y G, O, Gib, M   
          
Human GTAATGTCCAATTGTCTTAAG     449 
Gorilla GTAATGTCCAGTTGTCTTAAG c-Myb Gorilla only   
          
Human GTTTGTTT____TGCTGTGTTTTGAGAT     513, 515 
Gorilla GTTTGTTTTGTTTGTTTTGTTTTGAGAT HFH-2, HNF-3b, BR-C Z G, O, Gib, M   
          
Human CAGTGGCACAATCTCGGCTCA GATA-1, GATA-2, GATA-3   568, 573 
Gorilla CAGTGGCACAGTCTCAGCTCA cap Gorilla only   
          
Human ACTATAGGCATGTGCCACCA USF   649 
Gorilla ACTATAGGCAGGTGCCACCA Sn, Myo Gorilla only   
          
Human GTGCCACCACGCCAGGCTAAT     660, 669 
Gorilla GTGCCACCACACCAGGCTAGT AML-1 Gorilla only   
          
Human CGCCAGGCTAATTTTTTTTT S8, HFH-2   660, 669 
Gorilla CACCAGGCTAGTTTTTTTT SRY Gorilla only   
          
Human TTTTTTTTT__TTTGTATTTTT No difference   678, 682 
Gorilla TTTTTTTTGcgTGTGTATTTTT   Gorilla only   
          
Human GTATTTTTAGTAGAGATGGGG     692 
Gorilla GTATTTTTAGCAGAGATGGGG No difference Gorilla only   
          
Human TTTCCTTCCAGATTTCAGTCCT     953 
Gorilla TTTCCTTCCAAATTTCAGTCCT Lyf-1  Gorilla only   
          
Human TTCAGTCCTATAACTTTGGAC CdxA   966 
Gorilla TTCAGTCCTACAACTTTGGAC   all apes   
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(Table 7: Continued) 
Species Sequence Exclusive TFBS Occurrence Position 
Human TTGGACTCCCAACAGATTAAG Ik-2   981 
Gorilla TTGGACTCCCGACAGATTAAG   Gorilla only   
          
Human AGATCCCTTTCCCAAGTGACA USF, Ik-2   1094 
Gorilla AGATCCCTTTTCCAAGTGACA   Gorilla only   
          
Human TTGCAGTGAGCTGAGATTGTGC cap, AP-4   1330 
Gorilla TTGCAGTGAGCCGAGATTGTGC   all apes   
          
Human TGTGCCACTGTGCTCCAGCCT     1345 
Gorilla TGTGCCACTGCGCTCCAGCCT No difference all apes   
          
Human CCTGGATGACAGAGCAAGACTCTGTCTCA Skn-1   1358, 1375 
Gorilla CCTGGGTGACAGAGCGAGACTCCGTCTCA AP-1 all apes   
          
Human AAAAAAAAAACAAAAAACAAA BR-C Z,    1394 
Gorilla AAAAAAAAAAAAAAAAACAAA   all apes   
          
Human TGAAAACAAGGATAGAAATGT     1429 
Gorilla TGAAAACAAGAATAGAAATGT No difference all apes   
          
Human AACTTTACTACTTATGAGTGT     1595 
Gorilla AACTTTACTATTTATGAGTGT BR-C Z all apes   
 
 
 
 
Table 7: The sequences of human and gorilla were aligned and variable nucleotides 
between the species were noted. The variable nucleotide plus 10 nucleotides before and 
after were put into the TFSEARCH transcription factor binding site prediction program. 
The predicted transcription factors that are exclusive to one species are noted on the same 
line as that species’ nucleotide sequence. The occurrence of that change in one or more 
species is also noted. There were 31 nucleotide changes between human and gorilla, 17 of 
these were specific to gorilla and resulted in a loss of 12 transcription factor binding sites 
that were predicted to be in human.  
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3.13 Transcription factor binding sites may cause differential expression  
 Predicted transcription factor binding site differences were compared to regions 
that are highly conserved across mammals or have been previously identified as involved 
in the regulation of ACPP. There are 4 nucleotide changes in bonobo that produced a gain 
of 8 predicted transcription factor binding sites that occurred in regions responsible for 
upregulation or downregulation of expression as identified by Zelivianski et al. (2002), 
however no changes occurred in regions that are highly conserved.  In gorilla, there were 
a total of 9 nucleotide changes that produced 11 different predicted transcription factor 
binding sites in regions of upregulation or downregulation. A single change occurred in a 
peak of high conservation from position 133,518,721 to 133,518,804. This nucleotide 
change resulted in a loss of the Ik-2 transcription factor binding site in gorilla (Figure 13).   
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Figure 13: Location of changes in predicted transcription factor binding sites 
between human-bonobo and human-gorilla.  The location of the changes in predicted 
transcription factor binding sites aligned with other elements in the ACPP promoter show 
that only 1 change, found in gorilla, is located in a region of high conservation. This 
change in transcription factor binding site Ik-2, is highlighted with an arrow. A number of 
changes in both bonobo and gorilla occur in regions identified to be important in 
upregulation or downregulation of transcription.  
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Chapter 4 
 
 
Discussion  
 
 
4.1 Experimental Considerations 
 
4.1.1 The human ACPP reporter construct drives expression higher than the 
empty vector 
 It was determined that the human ACPP promoter construct is able to drive 
transcription to significantly higher levels than the empty vector by comparing the 
relative luminescence of each. The pGL4.10 [luc2] reporter vector contains no promoter 
and one would expect to see increased expression after the correct ligation of the ACPP 
upstream region of the luciferase reporter gene if it truly functions to promote 
transcription. In initial transient transfection experiments, the expression of the human 
ACPP construct was compared to the empty pGL4.10 [luc2] vector under no treatment 
and with 10 nM R1881, a synthetic androgen. The human promoter did have higher 
expression than the empty vector under both conditions. Others have previously 
suggested that a very conservative criteria for defining promoter activity is a > 10-fold 
increase in activity over the empty vector, and a more liberal definition of 2-fold or 
greater (Hoogendoorn et al., 2003; Chabot et al., 2007). Since the 1.7 kb human ACPP 
upstream region had previously been shown to effectively drive transcription (Shan et al., 
1997, 2003; Zelivianski et al., 2002) the requirement of a 10-fold increase is overly 
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conservative. In all of our experiments the magnitude of increase ranged from 2 to 5. 
Thus, we can conclude that our in vitro reporter system if functioning and that further 
experiments including the expression levels between hominoid species would be a 
reliable comparison.  
 
4.1.2 Problems and Inconsistencies 
 The relative luminescence ratios for the expression by the human ACPP construct 
varied from week-to-week (Figure 12). For the first transfection experiments, the mean 
ratio of luminescence is 2 to 5 times greater than the mean from other weeks. These first 
transfection experiments also had much higher standard errors (Figure 12). The data from 
subsequent weeks were more consistent under all experimental conditions and had lower 
standard errors. This could be caused by a few potential sources. First, the transfections 
in which the ratios were abnormally high were the first transfections performed and 
human error in properly performing the techniques may be a cause. Second, different 
DNA preps may not be of the same purity and cells may not react similarly to each prep. 
Third, cell culture conditions may also influence luminescence. Different culture 
environments, including small changes in pH, CO2 levels, humidity, or batch of reagents 
may influence the efficiency of the reaction. Because data from subsequent weeks have 
very small standard errors, it is unlikely that machine or pippetting error is a major source 
of variation. Other than the first transfections, all subsequent experiments have high 
consistency between individual transfections within one week and are likely reliable data. 
Some suggested solutions for the weekly variation include repeating the experiments 
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under the same experimental conditions, including the same batch of medium and serum, 
and re-purifying the human ACPP construct.    
 Chimpanzee was not included in the transient transfection experiments because of 
difficulty cloning the promoter into the TOPO TA and pGL4.10 [luc2] vectors. A 
restriction digest of this region in chimpanzee revealed an extra digestion site and 
subsequent attempts to clone in the promoter of other individuals also failed in both the 
TOPO TA and luciferase reporter vectors. This is not entirely problematic because of the 
high similarity between chimpanzee and bonobo; however, future experiments include 
creating the chimpanzee construct by making small procedural changes and repeating 
transient transfection experiments. 
 The first attempts at cloning the ACPP promoter into a vector included inserting 
the promoter directly into the pGL4.10 [luc2] vector. This had a low success rate and it 
was determined that cloning first into a TOPO TA vector could improve results. 
Subsequent cloning efforts were performed by TOPO TA cloning and purifying the insert 
from this vector for ligation into the luciferase reporter vector.  Even after this 
modification, cloning efficiency was still lower than desired. PCR was used to screen all 
colonies before purification of the plasmid.   
 At first, mini-prep plasmid purification of a 50 ml culture was performed to purify 
the TOPO TA vector containing the ACPP promoter. A restriction digest of this product 
produced the promoter fragment that was to be gel purified and ligated into the luciferase 
reporter vector. Because a large amount of product was lost through gel purification, 
larger digest reactions were performed and as a result, more purified plasmid was needed. 
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The midi-prep method of a 50 ml culture became the preferred method of purification 
after determining that the quantity of DNA produced by the midi-prep purification would 
be more beneficial to subsequent experiments.  
 
4.2 Levels of expression in bonobo and gorilla are consistent with mating 
behaviors 
 Chimpanzees and bonobos have a multimale/multifemale mating system in which 
the females mate with a large number of males per reproductive cycle (Goodall, 1986). 
They experience high levels of sperm competition and are the only hominoids to produce 
a copulatory plug (Dixson 1998 b). Many seminal proteins appear to have evolved under 
positive selection in chimpanzee (Clark and Swanson, 2005; Carnahan and Jensen-
Seaman, 2008). Gorillas are polygynous and likely experience little or no sperm 
competition. Some seminal proteins in gorillas are nonfunctional and are likely 
pseudogenes (Jensen-Seaman and Li, 2003; Carnahan and Jensen-Seaman, 2008). 
Humans are intermediate in the amount of sperm competition expected by their mating 
systems. In the transient transfection experiments of the pGL4.10 [luc2] constructs 
containing the hominoid ACPP promoter, the levels of expression produced by the 
constructs is proportional to the level of sperm competition in each species. The 
expression by the bonobo promoter is higher than all other hominoid species, while the 
gorilla expression is much lower than any other hominoid species. Human, orangutan, 
and gibbon expression levels were intermediate of the high and low extremes of bonobo 
and gorilla. While humans, gorillas, and gibbons are all expected to be experiencing no or 
low levels of sperm competition, gorilla may have the least sperm competition because of 
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the strong male-male physical competition that may prevent extra matings in gorilla 
females, more so than in the other hominoid species.  
 ACPP has the ability to cleave the semenogelins and liquefy ejaculated semen 
(Brillard-Bourdet et al., 2002). Increased expression of ACPP in bonobo may be 
occurring for a number of reasons. One possibility includes quicker degradation of the 
copulatory plug that was previously deposited by another male. Increased expression of 
this protein would be a reproductive strategy for a male to liquefy the first plug and 
deposit their own semen closer to the cervix of the female for an increased chance of 
fertilizing the egg. Another possibility includes degradation of one’s own copulatory 
plug. With sperm being trapped inside the thick coagulum, more rapid liquefaction of 
one’s own copulatory plug would allow the sperm to more quickly regain their motility 
and travel towards fertilization of the egg. Finally, increased expression of ACPP may be 
the result of scaling with ejaculate volume. Chimpanzees and bonobos have increased 
testes size (Harcourt et al., 1981) however data regarding volume of ejaculate is variable 
and may reflect method of collection as well as environment (captive or free) of the 
individual. Ejaculate volume estimates range from 1 ml (Martin and Gould, 1977) to 7 ml 
(Dixson, 1998b), compared to the human average of 2.5 ml (Martin and Gould, 1977). It 
would be interesting to determine if the increased expression of ACPP is consistent with 
increased ejaculate size, or if the concentration is higher in a smaller volume of ejaculate. 
Low expression levels in gorilla may also be explained similarly. A number of seminal 
proteins are pseudogenes in gorilla, as evidenced by the presence of premature stop 
codons; however, ACPP is not one of those genes (Clark and Swanson, 2005). While the 
protein coding sequence remains functional, changes in the regulation of the gene may be 
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responsible for the low levels of expression. Also, since gorilla has a smaller ejaculate 
volume than any of the other hominoid species, 0.4 ml, (Martin and Gould, 1977) the 
expression may be scaled to be proportional to concentrations in other volumes. 
Macaque, which has a multimale/multifemale mating system similar to chimpanzee and 
bonobo, also had significantly higher expression than many of the hominoids in the no 
treatment experiment. This study did not include Cercopithecoid relatives of macaque, 
however future experiments examining expression levels between Old World monkeys 
with varying mating systems would be interesting. 
 
4.3 Evolution at both levels 
 Changes that are responsible for phenotypic differences between species are likely 
the result of differences in the regulatory regions as well as the protein coding regions of 
genes (King and Wilson, 1975). The question that this study sought to answer was 
whether there was evidence for evolution of ACPP in both levels in the hominoids. From 
previous studies, the elevated Ka/Ks ratio in the chimpanzee lineage (1.16) is evidence 
for positive selection in the protein coding region of ACPP (Clark and Swanson, 2005).  
Increased expression levels seen in these luciferase assays also points to selection 
occurring in regions responsible for regulating ACPP expression.  While other genes may 
be pseudogenes in gorilla, the coding region of ACPP appears to be functional (Clark and 
Swanson, 2005). Given the extremely low expression levels in the luciferase assays, little 
or no ACPP may be produced in gorilla, although of course in vitro results may not 
necessarily be reflecting what is happening in vivo. Based on the differential expression 
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among hominoids in the transient transfection experiments as well as data from others on 
the protein coding regions of ACPP, I conclude that ACPP is evolving at both the protein 
and regulatory level in hominoids in response to sexual selection.  
 
4.4 Using TFBS to predict potential causes of differential expression 
 Regions that are essential for the regulation of gene expression may be located in 
areas that are highly conserved across mammals or vertebrates (Vavouri and Elfgar, 
2005).  Changes in these regions are likely to result in large expression differences. 
Transcription factor binding site prediction programs were used to determine if species-
specific nucleotide differences in the 1.7 kb region of the ACPP promoter contained in 
the bonobo or gorilla reporter constructs resulted in a gain or loss of  transcription factors 
predicted in these highly conserved regions. Compared with predictions from the human 
1.7 kb ACPP promoter sequence, gorilla lost one predicted factor, Ik-2, in a region that 
was highly conserved. The Ikaros transcription factor family is restricted to lymophcyte 
expression (Molnár and Georgopoulos, 1994) and therefore is does not likely explain the 
dramatic decrease in expression by the gorilla ACPP construct. Bonobo had no predicted 
changes in transcription factor binding sites in these regions compared to human. Other 
lines of evidence suggest that smaller, species-specific changes in gene expression may 
occur in regions that occur outside of highly conserved areas. Buckland et al. (2004) 
determined that up to 35% of human polymorphisms in promoters cause functional 
differences in expression and that the majority of these polymorphisms are not in 
conserved regions, or in regions containing a predicted transcription factor binding site. 
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Also, an estimated 32-40% of functional transcription factor binding sites in human are 
not functional in rodents, indicating a high turnover of transcription factor binding sites 
(Dermitzakis and Clark, 2002). The absence of many functional human transcription 
factor binding sites in rodents is further evidence for searching for hominoid-specific 
changes in regulation in areas outside of those conserved in mammals. When looking 
outside the highly conserved regions, a number of predicted differences occur between 
human and either bonobo or gorilla in the 1.7 kb region of ACPP from the reporter 
construct. It is likely that these changes are in part responsible for the differential 
expression of ACPP that is found among the hominoids. One way to determine which of 
these changes by itself or in combination is responsible for changes in expression 
includes site-directed mutagenesis to target individual nucleotide differences and measure 
expression levels. This method has been successful for others (Chabot et al., 2007) and 
would be an interesting future direction for this body of work.   
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Appendix 1: Alignment of Hominoid ACPP Construct (-1593 to +117) 
 
 
Human           CACATTCCAGGGCAT-CCTATGATCACATAAGAACACAATCCTCCTGCCACAGGTAAGCG 59 
Chimp           CACATTCCAGGGCAT-CCTATGATCACATAAGAACACAATCCTCCTGCCACAGGTAAGCG 59 
Bonobo          CACATTCCAGGGCAT-CCTATGATCACATAAGAACACAATCCTCCTGCCACAGGTAAGCG 59 
Gorilla         CACATTCCAGGGCAT-CCTATGATCACATAAGAACACAATCCTCCTGCCACAGGTAAGCG 59 
Orangutan       CACATTCCAGGGCAT-CCTATGATCACATAAGAACACAATCCTCCTGCCACAGGTAAGCG 59 
Gibbon          CACGTTCCAGGGCATTCCTATGATCACATAAGAACACAATCCTCCTGCCACAGCTAAGTG 60 
Macaque         CACATTCCAGGGCAT-CCGATGATCACATAAGAACACACTCCTCCTGCCACAGGTAAGCG 59 
                *** *********** ** ******************* ************** **** * 
 
Human           CAATGTACCAGGAAACAGGTTGCGGGTAAACCATTGTTCTCCCTCTGCCATTATGATAGA 119 
Chimp           CAATGTACCAGGAAACAGGTTGCGGGTAAACCATTGTTCTCCCTCTGCCATTAGGATAGA 119 
Bonobo          CAATGTACCAGGAAACAGGTTGCGGGTAAACCATTGTTCTCCCTCTGCCATTAGGATAGA 119 
Gorilla         CAATGTACCATGAAACAGGTTGCGGGTAAACCATTTTTCTCCCTCTGCCATTAGGATAGA 119 
Orangutan       CAATGTACCAGGAAACAGGTTGTGGGTAAACCATTGTTCTCTCTCTGCCATTAGGATAGA 119 
Gibbon          CAATGTACCAGGAAACAGGTTGTGAGTAAACCATTGTTCTCCCTCTGCCATTAGGACAGA 120 
Macaque         CAATGTACCCGGAAATGGGTTGTGGGTAAACCGTTGTTCTCCCTCTGCCATTAGGATAGG 119 
                *********  ****  ***** * ******* ** ***** *********** ** **  
 
Human           AATATCATGACAGGCAGCTCTGCCCCCAAATCTTGCAAAATCTCAATGTGCACCTCAAGT 179 
Chimp           AATATCATGACAGGCAGCTCTGCCCCCAAATCTTGCAAAATCTCAATGTGCACCTCAAGT 179 
Bonobo          AATATCATGACAGGCAGCTCTGCCCCCAAATCTTGCAAAATCWCAATGTGCACCTCAAGT 179 
Gorilla         AATATCATGACAGGCAGCTCTGCCCCCACATCTTGCAAAATCTCAATGTGCACCTCAAGT 179 
Orangutan       AATATCATGACAGGCAGCTCTGCCCCCAAATCTTGCAAAATCTCAATGTGCACCTCAAGT 179 
Gibbon          AATATCATGACAGGCAGCTCTGCCTCCAAATCTTGCAAAATCTCAATGTGCACCTCAAGT 180 
Macaque         AATGTCATGACAGGTAGCTCTGCCCCCAAATCTTGCAAAATCTCAATGTGCACCTCAAGT 179 
                *** ********** ********* *** ************* ***************** 
 
Human           TTGTATTGTTTTAGCCTATGATGGAACTGACAGGTTGGGGAAAATGGAAAGCAAAGTTCC 239 
Chimp           TTGTATTGTTTTAGCCTATGATGGAACTGACAGGTTGGGGAAAATGGAAAGCAAAGTTCC 239 
Bonobo          TTGTATTGTTTTAGCCTATGATGGAACTGACAGGTTGGGGAAAATGGAAAGCAAAGTTCC 239 
Gorilla         TTGTATTGTTTTAGCCTATGATGGAACTGACAGGTTGGGGAAAATGGAAAGCAAAGTTCC 239 
Orangutan       TTGTATTGTTTTAGCCTATGATGGAACTGACAGGTTGGGGAAAACGGAAAGCAAAGTTCC 239 
Gibbon          TTGTATTGTTCTAGCCTACGATGGAACTGACGGGTTGGGGAAAATGGAAAGCAAATTTCC 240 
Macaque         TTGTATTGCTTTAGCCCATGATGGAACTGACAGGTTGGGGAAAATGGAAAGCAAAGTTCC 239 
                ******** * ***** * ************ ************ ********** **** 
 
Human           ATCAGTCTGGATCGCCTTTTGTAGTGTCCCCAGTGAGATCATAGCTGGAGAGGCAAGGAT 299 
Chimp           ATCAGTCTGGATCGCCTTTTGTAGTGTCCCCAGTGAGATCATAGCTGGAGAGGCAAGGAT 299 
Bonobo          ATCAATCTGGATCGCCTTTTGTAGTGTCCCCAGTGAGATCATAGCTGGAGAGGCAAGGAT 299 
Gorilla         RTCAGTCTGGATCGCTTTTTGTAGTGTCCCCAATGAGATCATAGCTGGAGAGGCAAGGAT 299 
Orangutan       ATCAGTCTGGATCGCCTTTTGTAGTGTCCCCAATAAGATCATAGCTGGAGAGGCAAGGAT 299 
Gibbon          ATCAGTCTGGATTGTCTTTTGTAGTGTCCCCAATGAGATCATAGGTGGAGAGGCAAGGAT 300 
Macaque         ATCAGTCTGGATTGTATTTTGTAGTGTCACCAATGAGATCATAGCTGGAGAGGCAAGGGT 299 
                 *** ******* *  ************ *** * ********* ************* * 
 
Human           GTAACTCACTCAAAATTTAAGGCTTATGGCCAAAGTTGATGACTAATAATATAGAATTGT 359 
Chimp           GTAACTCACTCAAAATTTAAGGCTTATGGCCAAAGTTGATGACTAATAATATAGAATTGT 359 
Bonobo          GTAACTCACTCAAAATTTAAGGCTTATGGCCAAAGTTGATGACTAATAATATAGAATTGT 359 
Gorilla         GTAACTCACTCAAAATTTAAGGCTTATGGCCAAAGTTGATGACTAATAATATAGAATTGT 359 
Orangutan       GTAACTCACTCAAAATTTAAGGCTTATGGCCAAAGGTGATGACTAATAATATAGAATTGT 359 
Gibbon          GTAACTCACTCAAAATGTAAGGCTTATGGCCAAAGTTGGTGACTAATAATATAGAATTGT 360 
Macaque         GTAACTCACTAAAAATGTAAGGCTTATGGCCAAAGTTGATGACTAATAATACAGAATTAT 359 
                ********** ***** ****************** ** ************ ****** * 
 
Human           AGGTTTGGGCTTTTTGCTTTCTTAAAAAACTCTGTCAGGTTTGGAAAGGGACCTCCAATC 419 
Chimp           AGGTTTGGGCTTTTTGCTTTCTTAAAAAACTCTGTCAGGTTTGGAAAGGGACCTCCAATC 419 
Bonobo          AGGTTTGGGCTTTTTGCTTTCTTAAAAAACTCTGTCAGGTTTGGAAAGGGACCTCCAATC 419 
Gorilla         AGGTTTGGGCTTTTTGCTTTCTTAAAAAACTCTGTCAGGTTTGGAAAGGGACCTCCAATC 419 
Orangutan       AGGTTTGGGATTTTTGCTTTCTTAAAAAACTCTGTCAGGTTTGGAAAGGGACCTCCAATC 419 
Gibbon          AGGTTTGGGCTTTTTGTTTTCTTAAAAAACTCTGTCAGATTTGGAAAGGGACCACCAATC 420 
Macaque         AGGTTTGGGCTTTTTGTTTTCTTAAAAAACTCTGTCAGGTTTGGAAAGGGACCTCCAATC 419 
                ********* ****** ********************* ************** ****** 
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Appendix 1 (continued) 
 
Human           T-AATTTTGAGATACCACAGGTAATGTCCAATT-GTCTTAAGGTGTGACTAAAATTTTTC 477 
Chimp           T-AATTTTGAGATACCACAGGTAATGTCCAATT-GTCTTAAGGTGTGACTAAAATTTTTC 477 
Bonobo          T-AATTTTGAGATACCACAGGTAATGTCCAATT-GTCTTAAGGTGTGACTAAAATTTTTC 477 
Gorilla         T-AATTTTGAGATACCACAGGTAATGTCCAGTT-GTCTTAAGGTGTGACTAAAATTTTTC 477 
Orangutan       T-AATTTTGAGATACCACAGGTAATGTCCAATT-GTCTTAAGGTGTGACTAAAATTCTTC 477 
Gibbon          CTAGTTTTGAGATACCACAGGTAATGTCTAATT-GTCTTAAGGTGTGACTAAAATTTTTC 479 
Macaque         CCAATTTTGAGATGCCACGGGTAATGTCCAATTTGTCTTAAGGTGTGACTAAAATTTTTC 479 
                  * ********* **** ********* * ** ********************** *** 
 
Human           TTTTGTTT-GTTTTTTGTTGTTGTTTGTTTGTTT----TGCTGTGTTTTGAGATGGAGTC 532 
Chimp           TTTTGTTT-GTTTTTTGTTGTCGTTTGTTTGTTT----TGTTGTGTTTTGAGATGGAGTC 532 
Bonobo          TTTTGTTT-GTTTTTTGTTGTCGTTTGTTTGTTTGTTTTGTTGTGTTTTGAGATGGAGTC 536 
Gorilla         TTTTGTTT-GTTTTTTGTTGTTGTTTGTTTGTTTGTTTTGTTTTGTTTTGAGATGGAGTC 536 
Orangutan       TTTTTTTTTGTTTGTTGTTGTTTTTTGTTTGTTT----TGTTTTGTTTTGAGATGGAGTC 533 
Gibbon          TTTTGTTT-TTTGTTTGTTGTTGTTTATTTGTTTATTTTGTTTTGTTTTGAGATGGCATC 538 
Macaque         TTTGTTGT----TGTTGTTGTT-TTTGTTTGTTT-----GTTTCGTTTTGAGATGGAGTC 529 
                ***  * *      *******  *** *******     * *  ************  ** 
 
Human           TTGCTCTGTCACTCAGGCTGGAGTGCAGT-GGCACAATCTCGGCTCACTGCAACCTCCAC 591 
Chimp           TTGCTCTGTCACTCAGGCTGGAGTGCAGTTGGCACAATCTCGGCTCACTGCAACCTCCAC 592 
Bonobo          TTGCTCTGTCACTCAGGCTGGAGTGCAGT-GGCACAATCTCGGCTCACTGCAACCTCCAC 595 
Gorilla         TTGCTCTGTCACTCAGGCTGGAGTGCAGT-GGCACAGTCTCAGCTCACTGCAACCTCCAC 595 
Orangutan       TTGCTCTGTCACTCAGGCTGGAGTGCAGT-GGCACAATCTCAGCTCASTGCAACCTCCAC 592 
Gibbon          TTGCTCTGTCACCCAGGCTGGAGTGCAGT-GGCACAATCTCGGCTCACTGCAACCTCCAC 597 
Macaque         TTGCTCTGTAGCCCAGGCTGGAGTGCAGT-GGCACAATCTCGGCTTACTGCAACCTTCAC 588 
                *********  * **************** ****** **** *** * ******** *** 
 
Human           CTCCTGGGTTCAAGTGACTCTCCTGCCTC-GCCTCCCAGGTAGCTGGGACTATAGGCATG 650 
Chimp           CTCCTGGGTTCAAGTGACTCTCCTGCCTC-GCCTCCCAGGTAGCTGGGACTATAGGCATG 651 
Bonobo          CTCCTGGGTTCAAGTGACTCTCCTGCCTC-GCCTCCCAGGTAGCTGGGACTATAGGCATG 654 
Gorilla         CTCCTGGGTTYAAGTKACTCTCCTGCCTC-GCCTCCCAGGTAGCTGGGACTATAGGCAGG 654 
Orangutan       CTCCTGGGTTCAAGTGACTCTCCTGCCTC-ACTTCCCAGGTAGCTGGGACTACAGGCATG 651 
Gibbon          CTCCTGGGTTCAAGTGACTCTCCTGCCTCAGCCTCCCAGGTAGCTGGGACTACAGGCATG 657 
Macaque         CTTCTGGGTTCAAGTGATTCTCCTGCCTCAGTCTCCCAGGTAGCTGGGACTACAGGCATG 648 
                ** ******* **** * ***********    ******************* ***** * 
 
Human           TGCCACCACGCCAGGCTAATTTTTTTTT--TTTGTATTTTTAGTAGAGATGGGG-TTTCA 707 
Chimp           TGCCACCACGCCAGGCTAATTTTTTTTT--TTTGTATTTTTATTAGAGATGGGG-TTTCA 708 
Bonobo          TGCCCCCACGCCAGGCTAATTTTTTTTT--TT-GTATTTTTATTAGAGATGGGG-TTTCA 710 
Gorilla         TGCCACCACACCAGGCTAGTTTTTTTTGCGTGTGTATTTTTAGCAGAGATGGGG-TTTCA 713 
Orangutan       TGCCACCATGCCCAGCTAAAATTTTTYT----TGTATGTTTAGTAGAGATGGGG-TTTCA 706 
Gibbon          TGC-ACCATGCCCAGCTAATTTTTTTGT--TGTATATTTTTAGTAGAGATGGGGGTTTCA 714 
Macaque         TGCCACCACGCCCAGCTAATTTTTTTTT-----GTATTTTTAGTAGAGATGGGG-TTTCA 702 
                ***  ***  **  ****   *****        *** ****  ********** ***** 
 
Human           CCATGCTGGCCAGGCTGGTCTT-AACTCCTGACCTCAAGTGATCTGCCCACCTCGGCCTC 766 
Chimp           CCATGCTGGCCAGGCTGGTCTT-AACTCCTGACCTCAAGTGATCTGCCCACCTCAGCCTC 767 
Bonobo          CCATGCTGGCCAGGCTGGTCTT-AACTCCTGACCTCAAGTGATCTGCCCATCTCAGCCTC 769 
Gorilla         CCATGCTGGCCAGGCTGGTCTT-AACTCCTGACCTCAAGTGATCTGCCCACCTCGGCCTC 772 
Orangutan       CCATGCTGGCCAGGCTGGTCTTGAACTCCTGACC-CAAGTGATCTGCCCACCTCGGCCTY 765 
Gibbon          CCATGCTGGCCAGGCTGGTCTCGAACTCCTGACCTCAAGTGATCTGCCCGCCTCGGCCTC 774 
Macaque         CCATGCTGGCCAGGCTGGTCTTGAACTCCTGACCTCAAGTGATCTGCCCACCTCGGCCTC 762 
                *********************  *********** **************  *** ****  
 
Human           CCAAAGTGCTGGGATTACAGACATGAGCCACCACGCCCAGCCTAAAATTTTTCAAAATAA 826 
Chimp           CCAAAGTGCTGGGATTACAGACATGAGCCACCACGCCCAGCCTAAAATTTTTCAAAATAA 827 
Bonobo          CCAAAGTGCTGGGATTATAGACATGAGCCACCACGCCCAGCCTAAAATTTTTCAAAATAA 829 
Gorilla         CCAAAGTGCTGGGATTACAGACATGAGCCACCACGCCCAGCCTAAAATTTTTCAAAATAA 832 
Orangutan       CCAAARTGMWGGGATTACAGACCTGAGCCACCAGGCCCAGCCTAAAATTTTTCAAAATAA 825 
Gibbon          CCAAAGTGCTGGGATTACAGACGTAAGCCACCACACCCAGCCTAAAATTTTTCAAAATAA 834 
Macaque         CCAAAGTGCTGGGATTACAGACGTAAGTCACCATGCCCAGCCTAAAATTTTTCAAAATAA 822 
                ***** **  ******* **** * ** *****  ************************* 
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  Conserved Region 3 
Human           ACTTGCTGTTACTTTTCTTCTTTAATTTAAAAATACCTCTATAGGCTACATGAGAGTTTT 886 
Chimp           ACTTGCTGTTACTTTTCTTCTTTAATTTAAAAATACCTCTATAGGCTACATGAGAGTTTT 887 
Bonobo          ACTTGCTGTTACTTTTCTTCTTTAATTTAAAAATACCTCTATAGGCTACATGAGAGTTTT 889 
Gorilla         ACTTGCTGTTACTTTTCTTCTTTAATTTAAAAATACCTCTATAGGCTACATGAGAGTTTT 892 
Orangutan       ACTTGCTCTTACTTCTCTTCTTTAATTTAAAAATACCTCTATAGGCTACATGAGAGTTTT 885 
Gibbon          ACTTGCTCTTACTTTTCTTCTTTAATTTAAAAATACCTCTATAGGCTACATGAGAGTTTT 894 
Macaque         ACTTGCTCTTACTTTTCTTCTTTAATTTAAAAATACCTCTATAGGCTACATGAGAGTTTT 882 
                ******* ****** ********************************************* 
 
Human           TGAAAAAGTAGCCATGTTTGGCATGGAAATAGGCCCCAAATATGTCAACACCTGTATTTC 946 
Chimp           TGAAAAAGTAGCCATGTTTGGCATGGAAATAGGCCCCAAATATGTCAACACCTGTATTTC 947 
Bonobo          TGAAAAAGTAGCCATGTTTGGCATGGAAATAGGCCCCAAATATGTCAACACCTGTATTTC 949 
Gorilla         TGAAAAAGTAGCCATGTTTGGCATGGAAATAGGCCCCAAATATGTCAACACCTGTATTTC 952 
Orangutan       TGAAAAAGTAGCCATGTTTGGCATGGAAATAGGCCCCAAATATGTCAACACCTGTATTTC 945 
Gibbon          TGAAAAAGTATCCATGTTTGGATTGGAAATAGGCCCCAAATATGTCAACACCTGTATTTC 954 
Macaque         TGAAAAAGTAGCCATATTTGGCATGGAAATAGGCCTTAAATATGTCAATACTTGTATTTC 942 
                ********** **** *****  ************  *********** ** ******** 
 
          Conserved Region 2 
Human           CTTCCAGATTTCAGTCCTATAACTTTGGACTCCCAACAGATTAAGAATCACTGGTCTAAG 1006 
Chimp           CTTCCAGATTTCAGTCCTACAACTTTGGACTCCCAACAGATTAAGAATCACTGGTCTAAG 1007 
Bonobo          CTTCCAGATTTCAGTCCTACAACTTTGGACTCCCAACAGATTAAGAATCACTGGTCTAAG 1009 
Gorilla         CTTCCAAATTTCAGTCCTACAACTTTGGACTCCCGACAGATTAAGAATCACTGGTCTAAG 1012 
Orangutan       CTTCCAGATTTCAGTCCTACAACTTTGGACTCCCAACAGATTAAGAATCACTGGTCTAAG 1005 
Gibbon          CTTCCAGATTTCAGTCCTACAACTTTGGACTCCCAACAGATTAAGAATCACTGGTCTAAG 1014 
Macaque         CTTCCAGATTTCAGTCCTACAACTTTGGACTCCCAACAGATTAAGAATCACTGGTCTAAG 1002 
                ****** ************ ************** ************************* 
 
Human           GTTTCTAAAGTCAGGGTAGATCCCTTTCCCAAGTGACAGCCACAAATCCAACGCTGTATC 1066 
Chimp           GTTTCTAAAGTCAGGGTAGATCCCTTTCCCAAGTGACAGCCACAAATCCAACGCTGTATC 1067 
Bonobo          GTTTCTAAAGTCAGGGTAGATCCCTTTCCCAAGTGACAGCCACAAATCCAACGCTGTATC 1069 
Gorilla         GTTTCTAAAGTCAGGGTAGATCCCTTTTCCAAGTGACAGCCACAAATCCAACGCTGTATC 1072 
Orangutan       GTTTCTAAAGTCAGGGTAGATCCCTTTCCCAAGTGACAGCCACAAATCCAACACTGTATC 1065 
Gibbon          GTTTCTAAAGTCAGGGTAGATTCCTTTCCCAAGTGACAGCCACAAAGCCAATGCTGTATC 1074 
Macaque         GTTTCTAAAGTCAGGGTAGATCCCTTTCCCAA-TGACAGCCACAAAGCCA-CGCTGTATC 1060 
                ********************* ***** **** ************* ***   ******* 
 
Human           ATACCCTATCTAAAGAAAAGATAAAAGTAAACTGGCTTGGCACAGTGGCTCATGCCTGTA 1126 
Chimp           ATACCCTATCTAAAGAAAAGCTAAAAGTAAACTGGCTTGGCACAGTGGCTCATGCCTGTA 1127 
Bonobo          ATACCCTATCTAAAGAAAAGCTAAAAGTAAACTGGCTTGGCACAGTGGCTCATGCCTGTA 1129 
Gorilla         ATACCCTATCTAAAGAAAAGATAAAAGTAAACTGGCTTGGCACAGTGGCTCATGCCTGTA 1132 
Orangutan       ATACC-TACCTAAAAAAAAGATAAAAGTAAACTGGCAGGGCACGGTGGCTCATGCCTGTA 1124 
Gibbon          ATACCCTATCTAAAGAAAAGATAAAAGTAAACTGGCAGGGCACGGTGGCTCATGCCTGTA 1134 
Macaque         ATACCCTATCTAAAGAAAAGATAAAAGTAAACTGGCAGGGCACAGTGGCTCACGCCTGTA 1120 
                ***** ** ***** ***** ***************  ***** ******** ******* 
 
Human           ATCTCAGCACTTTGGGAGGCCAAGGCAGGCGGATCATGCGGTTAGGAGTTGGAGACCAGC 1186 
Chimp           ATCTCAGCACTTTGGGAGGCCAAGGCAGGCAGATCATGCGGTTAGGAGTTGGAGACCAGC 1187 
Bonobo          ATCTCAGCACTTTGGGAGGCCAAGGCAGGCAGATCATGCGGTTAGGAGTTGGAGACCAGC 1189 
Gorilla         ATCTCAGCACTTTGGGAGGCCAAGGCAGGCGGATCATGYGGTTAGGAGTTGGAGACCAGC 1192 
Orangutan       ATCTCAGCACTTTGGGAGGCCGAGGCAGGCAGATCGTGTGGTTAGGAGTTGGAGACTAGC 1184 
Gibbon          ATCTCAGCACTTTGGGAGGCCGAGGCAGGTGTATCATGTGGTTAGGAGTTGGAGACCAGC 1194 
Macaque         ATCTCAGCACTTTGGGAGGCTGAGGCAGGTGGATTACGAGGTCAGGAGTTCGAGACCAGC 1180 
                ********************  *******   **   * *** ******* ***** *** 
 
Human           CTAACCAACATGGTGAAACCCCGTCTCTACTAAAAATACAAAAATTCGCCGGGTGTGGTG 1246 
Chimp           CTAACCAACATGGTGAAACCCCGTCTCTACTAAAAATACAAAAATTCGCCGGGTGTGGTG 1247 
Bonobo          CTAACCAACATGGTGAAACCCCGTCTCTACTAAAAATACAAAAATTCGCCGGGTGTGGTG 1249 
Gorilla         CTAACCAACATGGTGAAACCCCRTCTCTACTAAAAATACAAAAATTCGCCGGGTGTGGTG 1252 
Orangutan       CTAACCAACATGGTGAAACCCCGTCTCTACTAAAAATACAAAAATTAGCCGGGTGTGGTG 1244 
Gibbon          ATAACCAACATGGTGAAACCCCGTCTCTACTAAAAATACAAAAATTAGCCGAGTGTGGTG 1254 
Macaque         CTAACCAACATGGTGAAACCCTGTCTCTACTAAAAATACAAAAATTAGCCAGGTGTGGTG 1240 
                 ********************  *********************** ***  ******** 
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Human           GTGCACGCCTGTAATCCCAGCTACTCAGGAAGACTGAAGCAGGAGAATTGCTTGAACCTG 1306 
Chimp           GTGCACGCCTGTAATCCCAGCTACTCAGGA-GACTGAAGCAGGAGAATTGCTTGAACCTG 1306 
Bonobo          GTGCACGCCTGTAATCCCAGCTACTCAGGA-GACTGAAGCAGGAGAATTGCTTGAACCTG 1308 
Gorilla         GTGCACGCCTGTAATCCCAGCTACTCAGGA-GACTGAAGCA---GAATTGCTTGAACCTG 1308 
Orangutan       GCGCCCGCCTGTAATCCCAGCTACTCAGGA-GGCTGAAGCAGGAGAATTGCTTGAACCTG 1303 
Gibbon          GCGCGCGCCTATAATCCCAGCTACTCAGGA-GGCTGAAGCAGGAGAATTGCTTGAACCTG 1313 
Macaque         GCGCATGCCTGTAATCCCAGCTACTCAGGA-GGCTGAGGCAGGAGAATTGCTTGAACTCA 1299 
                * **  **** ******************* * **** ***   *************    
 
Human           GGAGGCGGAGTTTGCAGTGAGCTGAGATTGTGCCACTGTGCTCCAGCCTGGATGACAGAG 1366 
Chimp           GGAGGCGGAGTTTGCAGTGAGCCGAGATTGTGCCACTGCGCTCCAGCCTGGGTGACAGAG 1366 
Bonobo          GGAGGCGGAGTTTGCAGTGAGCCGAGATTGTGCCACTGCGCTCCAGCCTGGGTGACAGAG 1368 
Gorilla         GGAGGCGGAGTTTGCAGTGAGCCGAGATTGTGCCACTGCGCTCCAGCCTGGGTGACAGAG 1368 
Orangutan       GGAGACGGAGTTTGYAGTGAGCCCAGATTGTGCCACTGCGCTCCAGCCTGGGTGACAGAG 1363 
Gibbon          GGAGGCGGAGTTTGCAGTGAGCCGAGATAGCGCCACTGCGCTCCAGCCTGGGTGACAGAG 1373 
Macaque         GGAGGCGGGCTTTGCAGTGAGCCAAGATCGTGCCACTGCACTCCAGCCTGGGTGACAGAG 1359 
                **** ***  **** *******  **** * *******  *********** ******** 
 
Human           CAAGACTCTGTCTCAAAAAAA--------AAAAAACAAAAAACAAAGATAAAAGTAAACT 1418 
Chimp           CGAGACTCCGTCTCAAAAAAACAAAAAACCAAAAAAAAAAAACAAAGATAAAAGTAAACT 1426 
Bonobo          AGAGACTCCATCTCAAAAAAA-AAAAAAAAAAAAAAAAAAAACAAAGATAAAAGTAAACT 1427 
Gorilla         CGAGACTCCGTCTCAAAAAAA-AAAAAAAAAAAAAAAAAAAACAAAGATAAAAGTAAACT 1427 
Orangutan       CGAGACTCKGTCTCAAAAAAA------------AAAAAAAAAAAAAGATAAAAGTAAACT 1411 
Gibbon          CGAGACTCCGTCTCAAAAAAAAAAAAAAXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX 1433 
Macaque         CAAAACTCCGTCCAAAAAAAA-------------AATAATAATAATGATAAAAGTAAACT 1406 
                  * ****  **  *******                                        
                Conserved Region 1 
Human           GAAAACAAGGATAGAAATGTCTGCTAACATGCTCTGTGACCTTGATCAACAGCTTTCCCC 1478 
Chimp           GAAAACAAGAATAGAAATGTCTGCTAACATGCTCTGTGACCTTGATCAACAGCTTTCCCT 1486 
Bonobo          GAAAACAAGAATAGAAATGTCTGCTAACATGCTCTGTGACCTTGATCAACAGCTTTCCCT 1487 
Gorilla         GAAAACAAGAATAGAAATGTCTGCTAACATGCTCTGTGACCTTGATCAACAGCTTTCCCC 1487 
Orangutan       GAAAACAAGAATAGAAATGTCTGCTAACATGCTCTGTGACCTTGATCAACAGCTTTCCCC 1471 
Gibbon          XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX 1493 
Macaque         GAAAACAAGAATAGAAATGTGTACTAACATGCTCTGTGACCTTGATCAACAGCTTTCCCC 1466 
                                                                             
 
Human           GCTCTTGGCCTTGGTGTCCTAACTTAAATGGGGAAACTGTGATCTCTCTCAGCTCAAAAT 1538 
Chimp           GCTCTTGGCCTTGGTGTCCTAACTTAAATGGGGAAACTGTGATCTCTCTCAGCTCAAAAT 1546 
Bonobo          GCTCTTGGCCTTGGTGTCCTAACTTAAATGGGGAAACTGTGATCTCTCTCAGCTCAAAAT 1547 
Gorilla         GCTCTTGGCCTTGGTGTCCTAACTTAAATGGGGAAACTGTGATCTCTCTCAGCTCAAAAT 1547 
Orangutan       GCTCTTGGCCTTGGTGTCCTAACTTAAATGGGGAAACTGTGATCTCTCTCAGCTCAAAAT 1531 
Gibbon          XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX 1553 
Macaque         ACTCTTGACCTTGGTGTCCTAACTTAAATGGGGAAACTGTGATCTCTCTCAGCTCAAAAA 1526 
                                                                             
 
Human           TTACATGACATTATTTACATA--CCAAACCTGCCCTACGCTTCCTGGAAACTTTACTACT 1596 
Chimp           TTACATGACATTATTTACATA--CCAAACCTGCCCTACGCTTCCTGGAAACTTTACTATT 1604 
Bonobo          TTACATGACATTATTTACATA--CCAAACCTGCCCTACGCTTCCTGGAAACTTTACTATT 1605 
Gorilla         TTACATGACAT-ATTTACATA--CCAAACCTGCCCTACGCTTCCTGGAAACTTTACTATT 1604 
Orangutan       TTACATGACATTATTTACATA--CCAAACCTGCCCTACGCTTCCTGGAAACTTTACTATT 1589 
Gibbon          XXXXXXXXXXXXXXXXXXXXATTCCAAACCTGCCCTACGCTTCCTGGAAACTTTACTATT 1613 
Macaque         TTATATGACATTATTTACATA--CCAAACCTGCCCTACGCTTCCTGGAAACTTTACTATT 1584 
• *********************************** * 
•  
          Conserved Region 4 
Human           TATGAGTGTGGCTCCTCCTTCCCTTTCAATCCCTTAATTAAATAGCTTCCCCTCTACAGG 1656 
Chimp           TATGAGTGTGGCTCCTCCTTCCCTTTCAATCCCTTAATTAAATAGCTTCCCCTCTACAGG 1664 
Bonobo          TATGAGTGTGGCTCCTCCTTCCCTTTCAATCCCTTAATTAAATAGCTTCCCCTCTACAGG 1665 
Gorilla         TATGAGTGTGGCTCCTCCTTCCCTTTCAATCCCTTAATTAAATAGCTTCCCCTCTACAGG 1664 
Orangutan       TATGAGTGTGGCTCCTCCTTCCCTTTCAATCCCTTAATTAAATAGCTTCCCCTCTACAGG 1649 
Gibbon          TATGAGTGTGACTCCTCCTTCCCTTTCAATCCCTTAATTAAAAAGCTTCCCCTCTACAGG 1673 
Macaque         TATGAGTGTGGCTCCTCCTTCC-TTTCAATCCCTTAATTAAATAGCTTCCCCTCTACAGG 1643 
                ********** *********** ******************* **************** 
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Human           CTTTTGAAGTGGTAGCAGTTCCTCCTAACTCCTGCCAGAAACAGCTCTCCTCAACATG 1714 
Chimp           CTTTTGAAGTGGTAGCAGTTCCTCCTAACTCCTGCCAGAAACAGCTCTCCTCAACATG 1722 
Bonobo          CTTTTGAAGTGGTAGCAGTTCCTCCTAACTCCTGCCAGAAACAGCTCTCCTCAACATG 1723 
Gorilla         YTTTTGAAGTGGTAGCAGTTCCTCCTAACTCCTGCCAGAAACAGCTCTCCTCAACATG 1722 
Orangutan       CTTTTGAAGTGGTAGCAGTTCCTCCTAACTCCTGCCAGAAACAGCTCTCTTCAGCATG 1707 
Gibbon          CTTTTGAAGTGATAGCAGTTCCTCCTAACTCCTGCCAGAAACAGCTCTCTTCAACATG 1731 
Macaque         CTTTTGAAGTGGTAGCAGTTCCTCCTAACTCCTGCCAGAAACAGCTGTCCTCAACATG 1701 
                 ********** ********************************** ** *** **** 
 
 
